CA1341605C - Synthetic antigen for the detection of aids-related disease - Google Patents
Synthetic antigen for the detection of aids-related diseaseInfo
- Publication number
- CA1341605C CA1341605C CA507755A CA507755A CA1341605C CA 1341605 C CA1341605 C CA 1341605C CA 507755 A CA507755 A CA 507755A CA 507755 A CA507755 A CA 507755A CA 1341605 C CA1341605 C CA 1341605C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- leu
- glu
- gln
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title description 7
- 208000012124 AIDS-related disease Diseases 0.000 title description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 285
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 89
- 241000700605 Viruses Species 0.000 claims abstract description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- 230000008878 coupling Effects 0.000 claims description 18
- 238000010168 coupling process Methods 0.000 claims description 18
- 238000005859 coupling reaction Methods 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000002860 competitive effect Effects 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 230000009918 complex formation Effects 0.000 claims description 4
- 239000012911 assay medium Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 30
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 9
- 102000014914 Carrier Proteins Human genes 0.000 claims 7
- 108010078791 Carrier Proteins Proteins 0.000 claims 7
- 230000008105 immune reaction Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 claims 4
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 108010071185 leucyl-alanine Proteins 0.000 claims 3
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 claims 2
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 102100034353 Integrase Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
- MHCLIYHJRXZBGJ-AAEUAGOBSA-N Trp-Gly-Cys Chemical compound N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CS)C(=O)O MHCLIYHJRXZBGJ-AAEUAGOBSA-N 0.000 claims 1
- 108010078428 env Gene Products Proteins 0.000 claims 1
- 108010050848 glycylleucine Proteins 0.000 claims 1
- 230000009851 immunogenic response Effects 0.000 claims 1
- 108010003700 lysyl aspartic acid Proteins 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 108010038745 tryptophylglycine Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 21
- 208000030507 AIDS Diseases 0.000 abstract description 6
- 239000012634 fragment Substances 0.000 abstract description 5
- 239000010836 blood and blood product Substances 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 229940125691 blood product Drugs 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 description 26
- 102000015636 Oligopeptides Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 239000000523 sample Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 241001430294 unidentified retrovirus Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- -1 gp65 Proteins 0.000 description 7
- 235000006109 methionine Nutrition 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010001513 AIDS related complex Diseases 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 101000906736 Escherichia phage Mu DNA circularization protein N Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 101000764570 Streptomyces phage phiC31 Probable tape measure protein Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical class OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- LKUOJDGRNKVVFF-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C(=O)C=CC1=O LKUOJDGRNKVVFF-UHFFFAOYSA-N 0.000 description 1
- NMHGKQRBLJOZEL-UHFFFAOYSA-N 4-methylbenzenecarbodithioic acid Chemical compound CC1=CC=C(C(S)=S)C=C1 NMHGKQRBLJOZEL-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 101500025412 Mus musculus Processed cyclic AMP-responsive element-binding protein 3-like protein 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- MOMWFXLCFJOAFX-UHFFFAOYSA-N OOOOOOOO Chemical compound OOOOOOOO MOMWFXLCFJOAFX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 101800001386 Peptide II Proteins 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002809 confirmatory assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000002602 scintillography Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
Abstract
Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.
Description
s1 ~34~60 5_ SYNTHETIC ANTIGEN FOR THE DETECTION
OF AIDS RELATED DISEASE
~
With the discovery that the diseases called lymphadenopathy syndrome and acquired immune deficiency disease (AIDS) are caused by an infectious retrovirus designated lymphadenopathy virus (LAV), human T-cell lymphotropic virus-III (I-ITLV-III), AIDS-related virus (ARV), or immune deficiency-associated virus (IDAV), there has become an immediate need to be able to detect potential vectors of the disease, such as blood from diseased individuals, which may be employed for transfusions or from which specific blood factors may be isolated.
To detect potential vectors of the disease, it is necessary to have viral proteins and/or antibodies to such proteins. Because of the hazards associated with growing the LAV/HTLV-III retrovirus, there is significant interest in establishing means for obtaining the viral proteins or their immunologic equivalents, which means do not necessitate handling large volumes of live, potentially infectious virus.
In choosing alternatives, one must be concerned with the fact that the viruses have been reported to be highly polymorphic, frequently changing as the retrovirus is passaged.
The various antigens of the retrovirus are described by Saxinger et al., Science (1985) .
227:1036-1038. See also Gallo et al., ibid. (1984) 224:500; Sarangadharn et al., ibid. 224:506; Barre-Sinoussi et al., ibid. (1983) 220:868; Montagnier et al., in Human T-Cell Leukemia/Lymphoma Virus, Gallo, Essex, Gross, eds. (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), 1984, p. 363. These may include, but are not limited to, p13, p18, p25, p36, gp43, p55, gp65, gp110, etc., where the numbers may differ depending upon the reporter.
Hopp and Woods, Proc. Natl. Acad. Sci. USA
(1981) 78:3824, describe criteria for selecting peptides as potential epitopes of polypeptides based on their relative hydrophilicity. In one study employing these criteria, a 12-amino acid peptide was synthesized that bound 9% of antibodies elicited by the native protein (Hopp, Molec. Inununol. (1981) 18:869). In general, Hopp/Woods criteria have been shown not to have a high predictive value. Furtherniore, epitopes have been demonstrated which are not hydrophilic (Kazim et al., Biochem. J. (1982) 203:201). Other studies of polypeptide antigenicity include Green et al., Cell (1982) 28:477, where peptides were employed which elicited antibodies, which antibodies were capable of binding to the native protein, while conversely antibodies which were elicited by the native protein failed to bind to the peptides; and Trainer et al., Nature (1984) 312:127, whose results with myohaemerythrin paralleled those of Green et al.
The complete nucleotide sequence of LAV is reported by Wain-Hobson et al., Cell (1985) 40:9. The complete sequence for HTLV-III is reported by Muesing et al., Nature (1985) 313:450, while the complete sequence for ARV is reported by Sanchez-Pescador et al., Science (1985) 227:484. All three viruses exhibit substantial nucleotide homology and are similar with respect to morphology, cytopathology, requirements for optimum reverse transcriptase activity, and at least some antigenic properties (Levy et al., Science (1984) 225:840; Shupbach et al., Science (1984) 224:503), and hence should be considered isolates of the same virus.
See also, Chang et al., Science (1985) 228:93.
Accurding to the invention peptide sequences capable of immunologically mimicking proteins encoded in the 2,~2 and/or env regions of the LAV/HTLV-III retrovirus are provided as reagents for use in the screening of blood and blood products for prior exposure to the retrovirus. The peptides are of at least 5 amino acids and can be used in various specific binding assays for the detection of antibodies to LAV/HTLV-III virus, for the detection of LAV/HTLV-III antigens, or as immunogens.
For the purpose of this disclosure, a virus is considered to be the same as or equivalent to LAV/HTLV-III if it substantially fulfills the following criteria:
(a) The virus is tropic for T-lymphocytes, especially T-helper cells (CD4+, according to the international nomenclature defined in Bernard et al., eds. Leucocyte Typing, New York: Springer Verlag, 1984);
(b) The virus is cytopathic for infected CD4+ cells (rather than transforming, as are HTLV-I and -II) ;
(c) The virus encodes an RNA-dependent DNA
polymerase (reverse transcriptase) which is Mg 2+_dependent (optimum concentration 5mM), has a pH
optimum of 7.8, is not inhibitable by actinomycin D, and can employ oligo(dT)12_18 as a primer for reverse transcription from its 3' LTR;
(d) The virus bands in a sucrose gradient at a density of approximately 1.16;
(e) The virus can be labeled with [3H)-uridine;
(f) The virus is substantially cross-reactive immunologically with the proteins encoded by the gaq and env regions of LAV/HTLV-III; and (g) The virus shares substantial nucleotide homology (approximately 75-100%) and amino acid sequence homology (approximately 75-10.0%) with LAV or HTLV-III.
Novel peptides are provided which immuno-logically mimic proteins encoded by the LAV/HTLV-III
retrovirus, particularly proteins encoded by the aaq and/or env regions of the viral genome. To accommodate strain-to-strain variations among different isolates, adjustments for conservative substitutions and selection among the alternatives where non-conservative substitutions are involveci, may be made. These peptides can be used individually or together for detection of the virus or of antibodies to the virus in a physiological sample. Depending upon the nature of the test protocol, the peptides may be labeled or unlabeled, bound to'a solid surface, conjugated to a carrier or other compounds, or the like.
The peptides of interest will be derived from the peptides encoded by the caq region or the env region. These peptides will be primarily derived from p55 or fragments thereof, e.g., p25 and p18, or gp150 and fragments thereof, e.g., gp4l. These peptides will be given Roman numerals, but will also be given numerical designations which are arbitrarily associated with the manner in which they were produced.
For the gag region, of particular interest are the coding regions extending from about base pair (bp) 450 to bp 731, particularly from about bp 450 to bp 545 (97) and bp 696 to bp 731 (71); from about bp 900 to bp 1421, particularly from about bp 921 to bp 1016, including bp 921 to bp 1010; bp 972 to bp 1016 (92); and bp 936 to bp 995 (17); or from about bp 1158 to about bp 1400, particularly bp 1164 to bp 1250 (90);
bp 1278 to bp 1385 (88); and bp 1320 to bp 1385 (15), of the LAV/HTLV-III retrovirus. (Numbering according to Wain-Hobson et al., supra.) F'or the env region, the regions of particular interest will be those polypeptides encoded within the bp 7210 to bp 7815 regions, particularly within bp 7231 to bp 7794, more particularly within about bp 7246 5 through bp 7317 (36), bp 7516 through bp 7593 (39), particularly bp 7543 through bp 7593 (79) and bp 7561 through 7593 (78), bp 7708 through bp 7779 (23), bp 7630 through bp 7689 (40), bp 7498 through bp 7554 (56).
The peptides of interest will include at least five, sometimes six, sometimes eight, sometimes 12, usually fewer than about 50, more usually fewer than about 35, and preferably fewer than about 25 amino acids included within a sequence coded for by the LAV/HTLV-III retrovirus. In each instance, desirably the oligopeptide will be as small as possible, while still maintaining substantially all of the sensitivity of the larger peptide. In some instances it may be desirable to join two or more oligopeptides which are non-overlapping in the same peptide structure or as individual peptides, which separately or together provide equivalent sensitivity to the parent.
The peptides may be modified by introducing conservative or non-conservative substitutions in the peptides, usually fewer than 20 number percent, more usually fewer than 10 number percent of the peptides being exchanged. In those situations where regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the differing epitopes of the different retroviral strains. In many instances to provide chemical and physical stability, methionine may be replaced by norleucine (Nor).
It should be understood that the polypeptides employed in the subject invention need not be identical to any particular LAV/HTLV-III polypeptide sequence, so long as the subject compounds are able to provide for immunological competition with proteins of at least one of the strains of the LAV/HTLV-III retrovirus.
1341fi0'S
Therefore, the subject polypeptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu;
asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
Usually, the sequence will not differ by more than twenty percent from the sequence of at least one strain of an LAV/HTLV-III retrovirus except where additional amino acids may be added at either terminus for the purpose of providing an "arm" by which the peptides of this invention may be conveniently immobilized. The arms will usually be at least 1 amino acid and may be 50 or more amino acids, more often 1 to 10 amino acids.
In addition, one or two amino acids may be added to the termini of an oligopeptide or peptide to provide for ease of linking of peptides one to another, for coupling to a support or larger peptide, for reasons to be discussed subsequently, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like.
Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, may be introduced at the C- or N-terminus of the peptide or oligopeptide to provide for a useful functionality for linking. Of particular interest is the presence of from 1 to 3 cysteines at the C- or N-terminus for linking to a support. The cysteine could be linked through a disulfide linkage to a dithio- or thio-functionalized support on a thioether linkage to an activated olefin support.
In addition, the peptide or oligopeptide sequences may differ from the natural sequence by the sequence being modified by terminal-NH2 acylation, e.g., acetylation, or thioglycolic acid amidation, terminal-carboxy amidation, e.g., ammonia, methylamine, etc. In some instances, these modifications may provide sites for linking to a support or other molecule.
The peptides and oligopeptides of interest will now be considered. The first peptides of interest will be derived from the gal region, particularly the protein referred to as p25 and p18.
The peptides for p25 are as follows:
The peptide I(15) encoded in the region bp 1320 to bp 1385 will have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X, where X is OH or NH2, wherein the amino terminal Y, e.g., Tyr or Cys, if present, is added to facilitate coupling of the peptide to a protein carrier.
The next peptide II (17) will be encoded by the region extending from about bp 936 to bp 995 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-X, where X is OH or NH2, wherein the amino terminal Y has been defined previously.
Of particular interest is the oligopeptide IIa:
(IIa) Y-Ala-Ala-Glu-Trp-Asp-Arg-Z-X, wherein X and Y have been defined previously and Z is a bond, an aniino acid which provides a means of linking, e.g., cysteine, tyrosine, etc., or taken together with X provides a functional group which may be used for linking, e.g., an olefin as in allyl or maleimidyl, dithio, etc.
The next peptide of interest, III (92), will be encoded by the region extending from about bp 972 to bp 1016 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X, wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 15 amino acids encoded by the LAV/HTLV III
genome.
The next peptide, IV (90), will be encoded by the region extending from about bp 1164 to bp 1250 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X, wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 29 amino acids encoded by the LAV/HTLV III
genome.
The peptide, V (88), will be encoded by the region extending from about bp 1278 to bp 1385 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X, wherein X and Y have been defined previously.
The next peptides of interest will be derived from the _q!2,2 protein region referred to as p18.
The next peptide of interest, VI (97), will be encoded by the region extending from about bp 450 through bp 545 and will have the following sequence,' where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X, wherein X and Y have been defined previously.
The next peptide of interest VII (71) will be encoded by the region extending from about bp 696 to bp 731. This peptide will include any oligopeptides coding for linear epitopes with the following amino acid sequence:
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr, wherein Y has been defined previously.
The next polypeptides of interest will be those derived from the env region, from gp110 (110kDa1).
The next peptide of interest, VIII, will be 5 encoded by the region extending from about bp 7246 through bp 7317 arid while coming within the general limitations indicated previously, will preferably have no more than 24 ami*no acids encoded by the LAV/HTLV III
genome.
10 The peptide of interest will generally have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X, where X is OH or NH2, wherein the carboxy terminal Z, e.g., Cys, if present, is an amino acid added to facilitate coupling of the peptide to a protein carrier.
Of particular interest is where 6, conveniently up to 4, of the naturally occurring C-terminal amino acids are deleted or substituted.
Oligopeptides contained within the above sequence of particular interest include:
(VIIIa) (49) Y-Arg-Val-Val-Gln-Ar.g-Glu-Lys-Arg-Z-X
(VIIIb) (50) Y-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-X.
The next peptides of interest will be derived from the env region known as gp4l.
The next peptide, IX (56), will be encoded by the region extending from about bp 7498 to bp 7554, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X, wherein X, Y and Z have been defined previously.
Uligopeptides contained within the above sequence of particular interest include:
(IXa) (56/39) Y-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X
and (IXb) (39/56) Y-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Z-X.
The next peptide of interest, X (39), will be encoded by the region from about bp 7516 through bp 7593 and has the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, where X is OH or NH2.
The next peptide, XI (40), will be encoded by the region extending from about'bp 7630 to 7689 where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X, wherein Y, X and Z have been defined previously.
The next peptide of interest, XII (23), will be encoded by the region extending from about bp 7708 through bp 7779. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
(XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X, wherein X, Y and Z have been defined previously.
The next peptide of interest, XIII (79), will be encoded by the region extending from about bp 7543 through bp 7593. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
(XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, wherein X and Y have been previously defined.
The next peptide of interest, XIIIa (78), will be encoded by the region extending from about bp 7561 through bp 7593. This peptide will include any oligopeptide coding for linear epitopes within the following amino acid sequence:
(XIIIa) (78) Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
Of particular interest is the use of the mercaptan group of cysteines or thioglycolic acids used for acylating terminal amino groups or the like for linking two of the peptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage. To achieve this, compounds may be employed having bis-haloacetyl groups, nitroarylhalides, or the like, where the reagents are specific for thio groups.
Thus, the linking between the two mercapto groups of the different peptides or oligopeptides may be a single bond or a linking group of at least two, usually at least four, and not more than about 16, usually not more than about 14 carbon atoms. Of particular interest, is where a member of a sequence from the c.ca region is linked to a member from the env region.
These chimeric peptides which may include non-amino acid linkages, may be further modified as will be described for the peptides and oligopeptides.
The subject peptides may be employed linked to a soluble macromolecular (e.g., a5kDa1) carrier.
Conveniently, the carrier may be a poly(amino acid), either naturally occurring or synthetic, to which antibodies are unlikely to be encountered in human serum. Illustrative polypeptides include poly-L-lysine, bovine serum albumin, keyhole limpet hemocyanin, bovine gamma globulin, etc. The choice is primarily one of convenience and availability.
With such conjugates, there will be at least one molecule of at least one subject peptide per macromolecule and not more than about 1 per 0.5kDa1, usually not more than about 1 per 2kDal of the macromolecule. One or more different peptides may be linked to the same macroniolecule.
The manner of linking is conventional, employing such reagents as P-maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid anhydride, glutaraldehyde, etc. The linkage may occur at the N-terminus, C-terminus or at a site intermediate the ends of the molecule. The subject peptide may be derivatized for linking, may be linked while bound to a support, or the like.
The compounds may be employed as labeled or unlabeled compounds depending upon their use. (By label is intended a molecule which provides, directly or indirectly, a detectable signal.) Various labels may be employed, such as radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates, cofactors or inhibitors, particles, e.g., magnetic particles, combinations of ligands and receptors, e.g., biotin and avidin, or the like. In addition, the peptides may be modified in a variety of ways for binding to a surface, e.g., microtiter plate, glass beads, chromatographic surface, e.g., paper, cellulose, silica gel, or the like. The particular manner in which the polypeptides are joined to another compound or surface is conventional and finds ample illustration in the literature. See, for example, U.S. Patent Nos.
4,371,515; 4,487,715; and patents cited therein.
Various assay protocols may be employed for detecting the presence of either antibodies to retroviral proteins or retroviral proteins themselves.
Of particular interest is using the peptide as the labeled reagent, where the label allows for a detectable signal, or binding the peptide, either directly or indirectly to a surface, where antibody to the peptide in the sample will become bound to the peptide on the surface. The presence of human antibody bound to the peptide can then be detected by employing a xenogeneic antibody specific for human immuno-globulin, normally both human IgM and IgG, or a labeled protein specific for immune complexes, e.g., Rf factor or S. aureus protein A.
Various heterogeneous protocols may be employed, either competitive or non-competitive.
Peptide may be bound to a surface or support ("support") and labeled antibody allowed to compete 5 with antibody in the sample for the limited amount of bound peptide. The amount of label bound to the support would be related to the amount of competitive antibody in the sample.
Antibody could be bound to the support and 10 the sample combined with labeled peptide. After contact of the reaction mixture with the bound antibody, the amount of label bound to the support would relate to the amount of cognate antibody in the sample.
15 Xenogeneic anti-human antibody, e.g., antibodies to the Fc of IgG and IgM (immunoglobulins), could be bound to a support. The sample would be contacted with the immunoglobulins and labeled peptide, whereby the amount of labeled peptide bound to the support would be indicative of the presence of the cognate antibodies.
Alternatively, homogeneous assays can be employed where the peptide is bound to an enzyme, fluorescer, or other label, where the binding of antibody to the peptide results in being able to discriminate between the label involved with a specific binding pair complex and label which is not involved in the complex. For assays involving such techniques, see for example U.S. Patent Nos. 3,817,837; 3,850,752;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074;
and 4,098,876.
As an illustration of the subject invention the subject peptides may be conjugated to a fluorescent molecule, such as fluorescein, rhodamine or umbelliferone. Various techniques may be used for detecting complex formation with antibodies, e.g., fluorescence polarization. In this assay the fluorescence polarization is different between complexed and uncomplexed peptide conjugate.
Apparatuses areavailable for measuring changes in fluorescence olarization e. TM
p , g., TDx supplied by Abbott Laboratories, Chicago, IL.
Illustrative of an assay technique is the use of sample containers, e.g., microtiter plate wells, where the subject polypeptides or conjugates thereof are adhered to the container bottom and/or walls either covalently or non-covalently. The sample, normally human blood or serum diluted in an appropriately buffered medium, is added to the container and a sufficient tinie allowed for complex formation between the polypeptide(s) and any cognate antibodies in the sample. The supernatant is removed and the container washed to remove non-specifically bound proteins.
A labeled specific binding protein which specifically binds to the complex is employed for detection. To the container may be added xenogeneic antisera to human immunoglobulin, particularly anti-(human IgM and IgG) in an appropriately buffered medium. The xenogeneic antisera will normally be labeled with a detectable label, e.g., radionuclide or enzyme. Instead of antisera, proteins specific for the immune complex may be employed, e.g., S. aureus protein A. The label may then be detected. For example, with an enzyme, after removal of non-specifically bound enzyme label, a developer solution is added. The developer solution will contain an enzyme substrate and possibly enzyme cofactors, chromogens, etc., which, upon reaction, provide a colored or fluorescent product which may be detected colorimetrically or fluorimetrically, respectively.
The peptides can be prepared in a wide variety of ways. The peptides, because of their relatively short size, may be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available today and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., 1984; and Tam et al., J. Am.
Chem. Soc. (1983) 105:6442.
Alternatively, hybrid DNA technology may be employed where a synthetic gene may be prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof, where the single strands overlap and can be brought together in an annealing medium so as to hybridize. The hybridized strands may then be ligated to form the complete gene and by choice of appropriate termini, the gene may be inserted into expression vectors, which are readily available today. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual, CSH, Cold Spring Harbor Laboratory, 1982. Or, the region of the viral genome coding for the peptide may be cloned by conventional recombinant DNA techniques and expressed (see Maniatis, supra).
DNA coding sequences which may be used for expressing peptides I - XIII are:
I (15) (TAT)GATTGTAAGACTATTTTAAAAGCATTGGGACCAG
CAGCTACACTAGAAGAAATGATGACAGCATGT
II (17) (TGT)TTAAAAGAGACCATCAATGAGGAAGCTGCAGAAT
GGGATAGAGTGCATCCAGTGCATGCA
III (92) GATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCA
GGCCAG
IV (90) TATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCA
AAAGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAA
ACTCTAAGA
V (88) AATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAAC
CCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCA
GCTACACTAGAAGAAATGATGACAGCATGT
VI (97) AGGGAGCTAGAACGATTCGCTGTTAATCCTGGCCTGTTA
GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTA
CAACCATCCCTTCAGACA
VII (71) GACACAGGACACAGCAGCCAGGTCAGCCAAAATTAC
VIII (36) GTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCA
AAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCA(TGT) IX (56) ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGA
TACCTAAAGGATCAACAG(TGT) X (39) AGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAG
CTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGC
XI (40) (TGT)AAATCTCTGGAACAGATTTGGAATAACATGACCT
GGATGGAGTGGGACAGAGAAATTAAC(TGT) XII (23) (TGT)CATTCCTTAATTGAAGAATCGCAAAACCAGCAAG
AAAAGAATGAACAAGAATTATTGGAATTAGATAAATGG
(GGA) XIII (79) AAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA
AAACTCATTTGC
Fragments from these sequences may be employed for expression of peptide fragments, conservative base changes can be made, where the modified codon(s) code for the same amino acid(s), or non-conservative changes in the coding sequence may be made, where the resulting amino acid may be a conservative or non-conservative change.
The coding sequence may be extended at either the 5'- or 3'-terminus or both termini to extend the peptide, while retaining its epitopic site. The extension may provide for an arm for linking, e.g., to a label, such as an enzyme, for joining two or all of the peptides together in the same chain, for providing antigenic activity, or the like.
For expression, the coding sequence will be provided with start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in a cellular host, e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.
The sequences by themselves, fragments thereof, or larger sequences, usually at least 15 bases, preferably at least 18 bases, may be used as probes for detectioii of retroviral RNA or proviral DNA.
Numerous techniques are described, such as the Grunstein-Hogness technique, Southern technique, Northern technique, dot-blot, improvements thereon, as well as other methodology. See, for example, WO 83/02277 and Berent et al., Biotechniques (1985) 3:208.
Conveniently, the polypeptides may be prepared as fused proteins, where the polypeptide may be the N- or C-terminus of the fused polypeptide. The resulting fused protein could be used directly by itself as the reagent or the subject polypeptide may be cleaved from all or a portion of the remaining sequence of the fused protein. With a polypeptide where there are no internal methionines, by introducing a methionine at the fusion site, the polypeptide may be cleaved employing cyanogen bromide. Where there is an internal methionine, it would be necessary to provide for a proteolytic cleavage site, e.g., poly-lysine and/or -arginine or combinations thereof, or the internal methionine could be substituted with an amino acid such as leucine and an N-terminal methionine added for cyanogen bromide cleavage. A wide variety of proteases, including dipeptidases, are well known and ;3 41 605 the appropriate processing signal could be introduced at the proper site. The processing signal may have tandem repeats so as to insure cleavage, since the presence of one or more extraneous amino acids will not 5 interfere with the utility of the subject polypeptides.
Depending upon the nature of the assay, the physiological sample, e.g., saliva, blood, plasma, or serum, may be pretreated by dilution into an assay medium, which will usually be an aqueous buffered 10 medium employing one of a variety of buffers, such as phosphate, tris, or the like. A preferred diluent is blotto (5% w/v nonfat dry milk, .01% thimerosal, .01%
Antifoam A in .01 M sodium phosphate, pH 7.2, and .15 M
NaCl). Usually the pH will be in the range of about 6 15 to 9. The sample will then be combined with the reagent in accordance with the appropriate protocol and sufficient time allowed for binding. Where a heterogeneous system is used, usually the stages will be followed by washes, to minimize non-specific 20 binding. At the end of the procedure, the label will be detected in accordance with conventional ways.
Besides the use of the subject peptides and their analogs in assays, the subject peptides may also find use by themselves or in combination in vaccines.
The peptides may be formulated in a convenient manner, generally at concentrations in the range of lug to 20mg/kg of host. Physiologically acceptable media may be used as carriers, such as sterile water, saline, phosphate buffered saline, and the like. Adjuvants may be employed, such as aluminum hydroxide gel, or the like. Administration may be by injection, e.g., intramuscularly, peritoneally, subcutaneously, intravenously, etc. Administration may be one or a plurality of times, usually at one to four week intervals.
The following examples are offered by way of illustration and not by way of limitation.
EXPERIMENTAL
Peptides 15, 71, 88, 90, 92 and 97 were assembled on a t-butyloxycarbonyl (BOC)-methylbenzyl-cysteine-phenyl-acetamidomethyl (PAM) polystyrene/di-vinylbenzene resin (Applied Biosystems, Inc., Foster City, CA). For carboxamide peptides 78 and 79 p-methylbenzhydrylamine polystyrene/divinylbenzene was used. Symmetrical anhydride couplings were carried out in an Applied Biosystems 430A synthesizer, except that glutamine and asparagine were coupled as hydroxybenzo-triazole esters. Benzyl based side chain protection and BOC alpha-amine protection were used. Tryptophan was protected by the formyl moiety, methionine was protected by its sulfoxide, and dinitrophenol was used for protecting histidine. Protecting groups were removed by conventional procedures.
Peptide 36 was assembled on a benzhydrylamine polystyrene/divinylbenzene resin in a Beckman 990 peptide synthesizer (Beckman Instruments, La Brea, CA).
Benzyl based side chain protection and BOC alpha-amine protection were used. All the residues were added by the direct dicyclohexylcarbodiimide method, except for glutamine which was coupled as the hydroxybenzotriazole ester.
Peptide 39 was synthesized on a benzhydryl-amine resin as described for peptide 36 with asparagine also being coupled as the ester.
When the peptides were radiolabeled, it was by acetylating the amino terminus with 3H-acetic acid and an excess of dicyclohexylcarbodiimide.
The peptides were deprotected and cleaved from the resin by the Tam "low-high" HF protocol (Tam et al., supra). Peptides 36, 39, 79, 78, 88, 90, 92 and 97 were extracted from the resin in 5% acetic acid and subjected to gel filtration chromatography in 5%
acetic acid. Peptides 15 and 71 were extracted in 0.5M
ammonium carbonate/0.OO1M dithiothreitol (DTT) and chromatographed in 0.05M ammonium carbonate/0.005M
B-mercaptoethanol. Fractions containing the peptide were pooled and lyophilized. The integrity of the synthetic products was assured by ninhydrin monitoring after each coupling and by analytical reverse phase chromatography and amino acid analysis.
Peptides 90, 92 and 97 were polymerized by oxidation of their sulfhydryls to intermolecular disulfides. Briefly, the lyophilized reduced peptide was dissolved in minimal 6M guanidine HC1/0.1M sodium phosphate, pH 9.0, and allowed to oxidize overnight at room temperature.
Peptides 15, 23, 36, 40, 49, 50 and 56 synthesized above were conjugated to bovine serum albumin (BSA) which had been derivatized with N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), essentially as described by Ishikawa et al., J. of Immunoassay (1983) 4:209.
To 2m1 of a BSA solution (20mg/ml in 0.1M
potassium phosphate, pH 7.0) at 30 C was added 1.5m1 of an SMCC solution (8mg/ml in dimethylformamide). The mixture was stirred magnetically for lhr, after which it was centrifuged to remove any precipitated albumin.
The clarified mixture was then subjected to gel filtra-tion on SephadexxG-25 equilibrated in O.1M potassium phosphate, pH 6Ø The protein-containing fractions, as determined by their absorbance at 280nm, were pooled and stored frozen at -70 C until needed.
The peptides synthesized above were dissolved in 0.1M sodium phosphate, pH 8.0 to a concentration of 5mg/ml (peptide 36), 8mg/ml (peptide 15) or 1.6mg/ml (peptide 39). To 1.5m1 of each solution was added 2mg of solid DTT. The solutions were stirred for 30min at 30 C, after which they were subjected to gel filtration chromatography on Sephadex G-10, equilibrated in 0.1M
potassium phosphate, pH 6Ø The tritium-containing fractions, as determined by scintillography of aliquots, were pooled and mixed with lml (0.5m1 for * Trade Mark peptide V) of SMCC-derivatized BSA. The resultant mixtures were stirred at 30 C for 12hr and then dialyzed exhaustively against water.
The other peptides were prepared in accordance with the procedures described above and conjugated to BSA in accordance with the above described procedures. The ratio of peptide to BSA was determined by employing radiotracers in accordance with conventional ways.
mols peptide mol BSA
I (15) 14 II (17) 5 VIII (36) 9 IX (56) 17 X (39) 6 XI (40) 18 XII (23) 30 *
* may be erroneous and could be as high as 55.
Analysis by ELISA
The lyophilized peptide or protein/peptide conjugate was dissolved in 6M guanidine HC1. The guanidine solutions were diluted in 0.05M
carbonate/bicarbonate buffer (pH 9.6) to a final peptide concentration of 8 to 40ug/ml just prior to plating in the 96-well plates. Fifty ul of peptide solution were aliquoted per microtiter well and incubated at 4 C overnight. Plates were then blocked with BLOTTO (5% [w/v] nonfat dry milk/0.01$
thimerosal/0.01% antifoam A in 0.O1M sodium phosphate, pH 7.2/0.15M sodium chloride) for one hour at 37 C.
Sera were diluted 1:100 with a 1:1 mixture of BLOTTO
and PBS (0.O1M sodium phosphate, pH 7.3/0.15M NaCl), and 50u1 of diluted sera was added to each well and incubated for one hour at 37 C. The sera were removed and the plates were washed three times in wash buffer (0.15M NaCl/0.05% (w/v) Tween 20) before adding 100u1 of the goat anti-human IgG/horseradish peroxidase conjugate (50% stock diluted 1:10,000 in 50mM sodium citrate/0.05$ Tween 20/1% heat-inactivated normal goat serum; obtained from Antibodies, Inc., Davis, CA) for one hour at 37 C. The conjugate was removed and the plates washed three times with 0.15M NaCl/0.05$ (w/v) Tween 20* The ELISA was developed by adding 100u1 per well of substrate solution (10mg 3,3',5,5'-tetramethylbenzidine in 50m1 0.05M sodium citrate, pH 7.0) for 30min at room temperature.
Reactions were stopped with 100u1 per well of 3N H2SO4-and the optical density at 450nm determined by an automated ELISA reader.
Summary of Table 1 Table 1 gives ELISA results for all petpides that are immunoreactive.
Peptides 49 and 50 are part of peptide 36.
Peptide 56 partially overlaps peptide 39.
Peptide 49-BSA reactive with 10/10 positve sera; not reactive with 2/2 negative sera.
Peptide 50-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 56-BSA reactive with 10/10 positive sera; not reactive wtih 2/2 negative sera.
Peptide 40-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 23-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 15-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 36-BSA reactive with 9/10 positive sera; not reactive with 2/2 negative-sera.
In a larger panel, peptide 56 which partially overlaps peptide 39, is not reactive with all sera that are reactive with peptide 39. This suggests that there * Trade Mark are at least two reactive epitopes within peptide 39 or that peptides 39 and 56 contain non overlapping reactive epitopes.
Peptide 23 (both conjugated to BSA and 5 unconjugated) was further tested against a larger panel of sera (23 positives, 8 negatives) and displays a sensitivity of 80-90%.
Summary of Table 2 10 Table 2 shows that two of the peptides derived from the cag region (#15 and #17) are reactive with LAV seropositive sera that are poorly reactive or unreactive with peptide 39. This supports the use of a combination of _qa2 and env peptides to produce a more 15 sensitive assay.
Summary of Table 3 Table 3 compares results obtained with peptides 15-BSA and 39 with results obtained with these 20 peptides physically mixed (15-BSA + 39) or chemically combined (thiol-oxidized 15 + 39).
The result obtained when positive samples are assayed with either the physical or chemical combination of peptides 15 and 39 is generally higher 25 than that obtained with either peptide alone. This is clearly demonstrated with samples 126, 131, 135, 138 and 1296.
Summary of Table 4 Table 4 compares results obtained with peptides 71, 78, 79, 88, 90, 92 and 97 in an ELISA
assay. All of the peptides except one provide better than 70% correlation for positives and two peptides had 100% correlation.
~
N r 1~ t0 = 01 J CO N Q1 ~ ~
N O O zt Vl N l!1 %O tP1M N
'~-. =.. p~ U1 V1 1~ O O O
d = = ~ Z r G. O N O O r O ~ O O O O
1 a ~ ~O P N O h r vl P Pf %D
N ~O r p~ O ~O f~ O~ O Yf O N N
m ^ N O N ^ .+ O O O
I O ~O h Qf O ~O e'- W Yf N V Yf < ~O =? h N N vl h N ~D N
N . = = . . ~
CO O r O ~ r r O O r ~ O O O
1 1~ v Q N h 1~ N f~ N 1~ V Lfl y ~D O ~O ~O ~O Pf N
m ^ ='= O O r N ^ N N ~ O O
P rf ^ ~O a0 Ot ~f %O vf N u1 EO
~O n t'f O r r= N a n o In o a ~o .o eo M ~ O o Q ^ ^ o o r r r r r o za _ ~ O 1 1~ O n {O O%
N N N N O ^ ~
W E'~ N ~O N f7 N Hf 61 ^ N C. O O O O O r N O O
,'+ F--1 1 Lff fp9 < O~ N ~ O ^ ~ /=Caf OI N N
a OA N O~ PI N v N 1~ O O
O ^ O O O O r O r r O d ~ .7 F=1 (V 7H.r 1 P. ~O Yf tO 1, N O ~ N
1-4 Q~ N ~O ~t ~n N N ~
> n In wl o W W m ^ ^ o 0 0 0 0 0 ^ r o 0 p~ u- o~ ao u- .. a P. %o o% v m a O N Lf! /'f Ff Yi A ~
1 N ~ < f9 r ^ r r m O r O O O O O O N N O O j Qi E"1 ~=
U ul~v .+
N
H H p r H W p v o N H1 V- Y- H VI N YI N M p v L
TL 61 Oi 07 N 61 N di 6) 61 01 = O 01 ?. ~ -N 2*t v+
A E-~ 0 H v Ha 44 OI a Ot N O O O O OI O
cp = N
W > O CO O uf N v) O
r'1 N N O O ~ O
O f/~ < Y .= r r r = = ~ .
(!~ Nr r r N ^ N r C O
o d ~ ~
cn d W
t1 Cry r r ~7C H - L r L r L r L r L r L r L r L r_ L r L r O b Q= ~õ~ O i6 Of0 0 0 4 O q O 4 O A O16 O A O q X X
~ W \ 7 \ 7 \~ \ 7 \ 7 \ O \ 7 \ 7 X p \ 7 \ O Y C-p X p X p X p X p X p x p X p X X ~ N N. vl A Np 4 QVI i0 VQI N QVI W Yf t! Vf A N N N C N A{11 ~ V L ~ O
bN A~
U ~ < O < O < O < O < ~ < I < < 01 Y 0! 3!
J L J t J t J t J L J L J t J C J L J t S L = t .-~
O
--~ ~ N V O f7 r a N
~ ~ ~ ^ ^ r r .~ ... ^ 1 O O O N
E 1 ~p > ci N ~p r ~ N Y1 N V' L1 r p ~+1 N O O
O N O O O O O
N V O~ ~D N O~ %D
1 ~O O R N O
J O N O O r O O
Q'.
',zõ~ H 1 \O Or ~O N P N N
tn O O O O O O O
rn w M H
t~ A
H~ Hz o W 6 ~ w N m a w o v ;X4 H ~ o ~ O u H
v~ H
W U
A W '"
H H ~~
W p r o ~ r O O N
O r O = O N ~
O r r ~ N O O
0 a A
`vx vx \x a~~N !" ~
O U] ~ CY CY C W i0 LO
0 Nmp Atpn i0appp ~Y ~~
C ocAL J.G JL Sr St UO W 5 r Ot V ^ ^ O~
~, p01 O N gfl ~ N
y N y~ r ~ ~O ~O
oa o" z M p o H Q~
A F N
U v F x ~ WA 0 ~ e~v, v o~ ~ ~
M ao v o ~ v v ~
r = . ^
Cn W 0 r N ~ O r r r C N O C G p p Wx F
A F
F C~i N o~ ~o v ~ ~ ~ t ' ~ N
N O~ ~ p W W N A w r r C C C C A C. C O O C.
a m :21 Fcn 1-4 Cn N
.'3' Q~i 0 ~O Mf ~q PI r'f ~ ~.Nj ~ 0 < V N
O O
O ^ O r ^ ^ O O O O o a ~n H
00 W ^
N A 7r~ 1 . ~ N ~ ~ ~ N ~ 10 ~O O ~ ~ ED
> 42 C2, 0 O O O C. p ^ = . , , O O O
O O
z H N
I ~
A
O~ W L> LO > o> L>
M Z 9 Or Or dr ~q N N N N y" Nr ~=r N~
~ ~ m d m m d ai oo 00 00 00 c~ O c ca ca cn CO.
u) cn a A H ¾ a H~a ~^ o 0 o N o _ W x O 14 O m ~ ~
~ N f7 M O ~ ra'1 O O N
a U F r ^ r . O , _ N o 0 " r ly '=, r .
O O W N N O O= O O
H
a ~ r r r r cn t=a W L r L r L r L r L r L r L r L q b q ~0 H Q~ H O q O~0 010 0 0 O O O q L r p4 C=~ E..~= \7 \3 \7 \~ \Z \, 0 7 0 ~ G 0 01 x x X01 X Y
~X oX V% laX OX 9X
C Y C O C Y C O C Y C 01 C 01 ~ ~ H ~ N ~ N ~ u-~0 N r0 M A N ~0 N A N i0 N
QQpQ ~O H i0 N 0 9 a.~ 0 ar L a+ L ~r L
C) G4 E E E E QE Eo N oE C O =r 01 r 01 r N r 01 f0 ar < < O NO ~ O N V ~ O < < a ~ ~0 a,+ ~0 s+ 10 a~
V a 0 J t J t J Z J l J Z J t J~ J= SC m S t S L S L S t N
(z~ ~ ^ ^ ^ ~ ~ ^ uNf P. ~ o~i ~ P. n a = AD ^ kO %D %o ~D
H
V
m N
v _ ~ 1~ !V ~O P- N
X N O ~ O% P1 Y7 S~ 'O 16 .6 N 01 O = =
1 ~ N C N C C ~ C C C C ~ ~
r O
t`
O O O O
v v v v v v N N N N N N N N
A A C A A C C A G C C C A A
M
O N do %O in r !V N N N b ~
rf e'1 N ~ O Yf Uf Yf O O N
O ~- ~- O -O ~
1'9 O N N O e1 N ~ r N ~ ~ o 0 o e o 0 0 0 0 0 0 0 N
q N N N N N N N M N N tl1 N N N
GGG Yf Y1 ~1 ~1 !~ ~ ~s ~ !~ ~ ~ ~1 >1 C
O
u N
L~
O, O O f'1 Pf Qt N Nf 1D p .- N O h > O O V' 10 O 4) 1-~ PI '? RI O N N
r O N ~ N N N O
m O Q~ N N
N. .
- O
.
r L r L r L r L r L r L r L r L r L r L r 0 O r L.
~ d \ O q O q O~0 o A O q O q O q O N O A O~tl O~0 >r >r CX Vx 9X ~7~t ~x 9x ax oX ~X ~X ~x Vx =rl 0 +-o qm cm em cm cm cm cJI cm Cm Cm Cm Cm +~ L N L. YI i0 N i0 N i0 N q N q N /6 N ~b N O N N N '0 N A N
rNC ~~ A pE pE QE QE QE QE QE pE QE
O O Q O O < 8 < 6 < O < O < < < < O <~ < O < d <
C) d Y d Y J t J L J t J t J t J t J L J L J t J t -J L J t M V O N ~ YI 1p P {b Ct O N
L O 1 O N N N N N N N N N Pf NI NI
W N vf ~= V r .. ~ .-. ~ ~ .- .- ~ r- ~
aa N
x 9 O C O O O
O
0 C= 0 0 ^ a M Ln Y1 an - ~ O
O ~ o 0 C. 0 n a 'r` C C C
%. C
C
O
V
~
T N
! O%
~ 40 C C C
O
r ~ r .d r O '0 '0 i0 7 7 7 x x x rO LO LO
~ N L M L a+ L y L
~ '- CI r O r ~i r d1 Q Y d1 {b/ m d Y m Y
U xt xt St rL
N p ly %O O1 O1 O1 W Y `p ao cc ao cC
H
1 1 O CO N=-+ m 00 m %~o L+'1 %O 01, u'1 N M 7=--~ %D L/1 %O ~,o O M u'1 N O M
a0 1 N M rn a0 N rr .4 .7 O~Y M O Q~ M .-~ O--+ 00 r- Lr1 J611 ao N t- r- I O
t~ 1 u'1~70N.i.-~ Z NN.--~O. NOZO0000~00 I N r=+
I . . . . . . . . . . . . . . . . . . . . 1 . \
I O %D I
(~!] j ~A p~p ~p -.:r %D ,--4 M -,Y N%O ~t ID tV (- O 00 N --,T ~7 N M O %O N
M I
V) O~ I -.7 O 00 ~,O -zr ~ CG cO1 00 ID -:T 00 00 =-+ m Ln "O I-O N 1- N. u'1 -T N~O 00 I O 00 C', f~ 1 C1 0p O N=--~ M m OZ Ln ~--~ u"1 O c'n M u1 --I 1- Lf'1 Z cV --1--4.-+ N.--~ ,-+ 1 M =-+
1 . . . . . . . . . . . . . . . . 1 . \
d i N.~ N.-~ .-~ ~ I O o0 V) I I
H I I
a ~O O--1 %.O %O Lr1 N O u1 %0 N 1~ 00 L/1 N 00 =--~ ~ oO O-4 ON O vl O( r+ 1 t- un ~ .., -1 M M Ln -4 00 cn .p O Orn o0 r+ 00 7 A A O 00 O% N.G 0 00 1.- 1 0 00 .7..~ n 1 ~t fll tr1 -.T NV1 N M N-4 Vl M M N1 N M.--4 M',Z, Z r+ O O-4 ~--~ -4 O O I N ~--~
Q I , . 1 . \
1 1 O ~
I I "a z I I
po 1 00 . - 4 NUr1 t- L!1 O u'1 I : r O-+ 1~0 ON -4 ~O N cM N-7 O vl Wl O r=+
N I
r- r- I Lf1 ~t O O% r, v1 cY1 00 1.0 oo N NO'~ ON O N~Y Vl A A~D r- ON - u1 N
u1 N I O 00 O, u'1 C~1 M M M~T N i~ M O~ 1O N M M N f~ N',~ z.--~ =--~ ~~--4 ~~ I fV ~
'p I . . . . . . . . . . . . . . . . . . . . . . . . I . \
V 1 N N N = N~ ~~ =--~ = N I 0 00 tC '~
I I
r, I O N N ao =+ 00 r- O~o 00 N O~o N M n ao 00 %.O -=+ oo N O-4 00 M I
00 1 =-i =-r t- ON OLr1 Ln 00 v1 Lr1 17 rY t` N A~T O% u'1 A N O M N rn Orn -O% oo 1 O 00 ao 11,0 O% Mr- (N M.-~.-+cNOM r- t-~7 Z ^~--~0 z00- 0 0 1 cV ~+
~ I \
1\ I .-i ~ . ~ . . . . . . . . ~ . . . N N . . . . . . . I O cn ri 1 M I I '-"
I
r~ Q 1 O+ a .o O ir1 ~o N m - . T O MU.1 % O ~--~ ;r m Lf'1 O% .-r Oo M f- m - - T
O1% u1 O-+ i vl O t, 00 O0 L!1 -.t Ln N 7 CM c*1 00 O m M.7 ON A O.-y - 1- %C ui %O N O oD
w0 0% N rn cl1 00 =-4 %D =-~ ~o 00 0~ O N C. 1~ a0 O Z Z~O ~o u) ~7 M~Y V1 ~1 t~ =-+
~ E 4 . . ~ ~ . . . ~ . . . . . . . . I O V1 U) 1 I ""
ww 1 1 a%A 1~--4 0 u"1%CN.-+Odo OoC00~nO~DON N.--i v10oN.-40~.71-Q N 1 0 cNONNC=1NM0--+Ln Ln 0 o00 ~r- mr- tncocor- Lnr- I O 00 wpq O~ 1 N N ~ r+ '~ r+r+ ~--~0=-+~"7O:G OOOOOOOO ~--~ =-+
N H 1 . . . . . . . . . . . . . . . . . . . . . . . . . . I . \
oN Hz i O
tA 6 I I ~
W I I
Afj+ 1 I
N O I I
H
048 u) a~ l wo ~a a I I
a ~-+ =r+ 1 I
H 'b " I
L*a U 41 =H 1 I N N 7 O W 6 m 1 tn m cn m cn cn (n (D m cn w u) tn m w (n ED rn m v) 1 6 r1 =~
H !+ o I N N Gl G1 C1 C- Cl N Ol GJ C- Gl N C- U1 Gl G/ N N Cl o 0 0 0 0 0 0 o I ~+ a+~
z w =r1 a 7, 7+ D+ >1 >+ D+ 71 71 7, >, 7~ 7, f. R~~~ G 1/. G I rl ~ r1 oA wo I
U) p 1,,, I i G cn o ~-4W o v 1 i 0 w dEx~ U~ I
4-4 ~ a U f=+ I
. ~ i G-0 . u w ,I G
o I 1 w " o Ol Z I 1 o u H a.+
I r- O'T Ln oo ~t Ln M--T Ln 1- 0 -4 ao cn .-4 .-~ Orn a+ .-4 r1 -11 I'D I+1 Cd N Gl W ~ 1 N M N N N M('M LP1 ul u1 Lf1 fV N M t=1 l+l fYl O CV ~ M .-I ln -7 ~ ~r-+ ( 7 Y+ U) .-4 -, . . 4 . -4 .-4 .-1 .-r .-4 u') .-, >+ z Z Z ~o %o Z Z Z U t*+
a- I I
E~-~ ~n I I
Prepared as described in U.K. application Serial No. 83/24800, filed September 15, 1983.
OF AIDS RELATED DISEASE
~
With the discovery that the diseases called lymphadenopathy syndrome and acquired immune deficiency disease (AIDS) are caused by an infectious retrovirus designated lymphadenopathy virus (LAV), human T-cell lymphotropic virus-III (I-ITLV-III), AIDS-related virus (ARV), or immune deficiency-associated virus (IDAV), there has become an immediate need to be able to detect potential vectors of the disease, such as blood from diseased individuals, which may be employed for transfusions or from which specific blood factors may be isolated.
To detect potential vectors of the disease, it is necessary to have viral proteins and/or antibodies to such proteins. Because of the hazards associated with growing the LAV/HTLV-III retrovirus, there is significant interest in establishing means for obtaining the viral proteins or their immunologic equivalents, which means do not necessitate handling large volumes of live, potentially infectious virus.
In choosing alternatives, one must be concerned with the fact that the viruses have been reported to be highly polymorphic, frequently changing as the retrovirus is passaged.
The various antigens of the retrovirus are described by Saxinger et al., Science (1985) .
227:1036-1038. See also Gallo et al., ibid. (1984) 224:500; Sarangadharn et al., ibid. 224:506; Barre-Sinoussi et al., ibid. (1983) 220:868; Montagnier et al., in Human T-Cell Leukemia/Lymphoma Virus, Gallo, Essex, Gross, eds. (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), 1984, p. 363. These may include, but are not limited to, p13, p18, p25, p36, gp43, p55, gp65, gp110, etc., where the numbers may differ depending upon the reporter.
Hopp and Woods, Proc. Natl. Acad. Sci. USA
(1981) 78:3824, describe criteria for selecting peptides as potential epitopes of polypeptides based on their relative hydrophilicity. In one study employing these criteria, a 12-amino acid peptide was synthesized that bound 9% of antibodies elicited by the native protein (Hopp, Molec. Inununol. (1981) 18:869). In general, Hopp/Woods criteria have been shown not to have a high predictive value. Furtherniore, epitopes have been demonstrated which are not hydrophilic (Kazim et al., Biochem. J. (1982) 203:201). Other studies of polypeptide antigenicity include Green et al., Cell (1982) 28:477, where peptides were employed which elicited antibodies, which antibodies were capable of binding to the native protein, while conversely antibodies which were elicited by the native protein failed to bind to the peptides; and Trainer et al., Nature (1984) 312:127, whose results with myohaemerythrin paralleled those of Green et al.
The complete nucleotide sequence of LAV is reported by Wain-Hobson et al., Cell (1985) 40:9. The complete sequence for HTLV-III is reported by Muesing et al., Nature (1985) 313:450, while the complete sequence for ARV is reported by Sanchez-Pescador et al., Science (1985) 227:484. All three viruses exhibit substantial nucleotide homology and are similar with respect to morphology, cytopathology, requirements for optimum reverse transcriptase activity, and at least some antigenic properties (Levy et al., Science (1984) 225:840; Shupbach et al., Science (1984) 224:503), and hence should be considered isolates of the same virus.
See also, Chang et al., Science (1985) 228:93.
Accurding to the invention peptide sequences capable of immunologically mimicking proteins encoded in the 2,~2 and/or env regions of the LAV/HTLV-III retrovirus are provided as reagents for use in the screening of blood and blood products for prior exposure to the retrovirus. The peptides are of at least 5 amino acids and can be used in various specific binding assays for the detection of antibodies to LAV/HTLV-III virus, for the detection of LAV/HTLV-III antigens, or as immunogens.
For the purpose of this disclosure, a virus is considered to be the same as or equivalent to LAV/HTLV-III if it substantially fulfills the following criteria:
(a) The virus is tropic for T-lymphocytes, especially T-helper cells (CD4+, according to the international nomenclature defined in Bernard et al., eds. Leucocyte Typing, New York: Springer Verlag, 1984);
(b) The virus is cytopathic for infected CD4+ cells (rather than transforming, as are HTLV-I and -II) ;
(c) The virus encodes an RNA-dependent DNA
polymerase (reverse transcriptase) which is Mg 2+_dependent (optimum concentration 5mM), has a pH
optimum of 7.8, is not inhibitable by actinomycin D, and can employ oligo(dT)12_18 as a primer for reverse transcription from its 3' LTR;
(d) The virus bands in a sucrose gradient at a density of approximately 1.16;
(e) The virus can be labeled with [3H)-uridine;
(f) The virus is substantially cross-reactive immunologically with the proteins encoded by the gaq and env regions of LAV/HTLV-III; and (g) The virus shares substantial nucleotide homology (approximately 75-100%) and amino acid sequence homology (approximately 75-10.0%) with LAV or HTLV-III.
Novel peptides are provided which immuno-logically mimic proteins encoded by the LAV/HTLV-III
retrovirus, particularly proteins encoded by the aaq and/or env regions of the viral genome. To accommodate strain-to-strain variations among different isolates, adjustments for conservative substitutions and selection among the alternatives where non-conservative substitutions are involveci, may be made. These peptides can be used individually or together for detection of the virus or of antibodies to the virus in a physiological sample. Depending upon the nature of the test protocol, the peptides may be labeled or unlabeled, bound to'a solid surface, conjugated to a carrier or other compounds, or the like.
The peptides of interest will be derived from the peptides encoded by the caq region or the env region. These peptides will be primarily derived from p55 or fragments thereof, e.g., p25 and p18, or gp150 and fragments thereof, e.g., gp4l. These peptides will be given Roman numerals, but will also be given numerical designations which are arbitrarily associated with the manner in which they were produced.
For the gag region, of particular interest are the coding regions extending from about base pair (bp) 450 to bp 731, particularly from about bp 450 to bp 545 (97) and bp 696 to bp 731 (71); from about bp 900 to bp 1421, particularly from about bp 921 to bp 1016, including bp 921 to bp 1010; bp 972 to bp 1016 (92); and bp 936 to bp 995 (17); or from about bp 1158 to about bp 1400, particularly bp 1164 to bp 1250 (90);
bp 1278 to bp 1385 (88); and bp 1320 to bp 1385 (15), of the LAV/HTLV-III retrovirus. (Numbering according to Wain-Hobson et al., supra.) F'or the env region, the regions of particular interest will be those polypeptides encoded within the bp 7210 to bp 7815 regions, particularly within bp 7231 to bp 7794, more particularly within about bp 7246 5 through bp 7317 (36), bp 7516 through bp 7593 (39), particularly bp 7543 through bp 7593 (79) and bp 7561 through 7593 (78), bp 7708 through bp 7779 (23), bp 7630 through bp 7689 (40), bp 7498 through bp 7554 (56).
The peptides of interest will include at least five, sometimes six, sometimes eight, sometimes 12, usually fewer than about 50, more usually fewer than about 35, and preferably fewer than about 25 amino acids included within a sequence coded for by the LAV/HTLV-III retrovirus. In each instance, desirably the oligopeptide will be as small as possible, while still maintaining substantially all of the sensitivity of the larger peptide. In some instances it may be desirable to join two or more oligopeptides which are non-overlapping in the same peptide structure or as individual peptides, which separately or together provide equivalent sensitivity to the parent.
The peptides may be modified by introducing conservative or non-conservative substitutions in the peptides, usually fewer than 20 number percent, more usually fewer than 10 number percent of the peptides being exchanged. In those situations where regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the differing epitopes of the different retroviral strains. In many instances to provide chemical and physical stability, methionine may be replaced by norleucine (Nor).
It should be understood that the polypeptides employed in the subject invention need not be identical to any particular LAV/HTLV-III polypeptide sequence, so long as the subject compounds are able to provide for immunological competition with proteins of at least one of the strains of the LAV/HTLV-III retrovirus.
1341fi0'S
Therefore, the subject polypeptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu;
asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
Usually, the sequence will not differ by more than twenty percent from the sequence of at least one strain of an LAV/HTLV-III retrovirus except where additional amino acids may be added at either terminus for the purpose of providing an "arm" by which the peptides of this invention may be conveniently immobilized. The arms will usually be at least 1 amino acid and may be 50 or more amino acids, more often 1 to 10 amino acids.
In addition, one or two amino acids may be added to the termini of an oligopeptide or peptide to provide for ease of linking of peptides one to another, for coupling to a support or larger peptide, for reasons to be discussed subsequently, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like.
Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, may be introduced at the C- or N-terminus of the peptide or oligopeptide to provide for a useful functionality for linking. Of particular interest is the presence of from 1 to 3 cysteines at the C- or N-terminus for linking to a support. The cysteine could be linked through a disulfide linkage to a dithio- or thio-functionalized support on a thioether linkage to an activated olefin support.
In addition, the peptide or oligopeptide sequences may differ from the natural sequence by the sequence being modified by terminal-NH2 acylation, e.g., acetylation, or thioglycolic acid amidation, terminal-carboxy amidation, e.g., ammonia, methylamine, etc. In some instances, these modifications may provide sites for linking to a support or other molecule.
The peptides and oligopeptides of interest will now be considered. The first peptides of interest will be derived from the gal region, particularly the protein referred to as p25 and p18.
The peptides for p25 are as follows:
The peptide I(15) encoded in the region bp 1320 to bp 1385 will have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X, where X is OH or NH2, wherein the amino terminal Y, e.g., Tyr or Cys, if present, is added to facilitate coupling of the peptide to a protein carrier.
The next peptide II (17) will be encoded by the region extending from about bp 936 to bp 995 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-X, where X is OH or NH2, wherein the amino terminal Y has been defined previously.
Of particular interest is the oligopeptide IIa:
(IIa) Y-Ala-Ala-Glu-Trp-Asp-Arg-Z-X, wherein X and Y have been defined previously and Z is a bond, an aniino acid which provides a means of linking, e.g., cysteine, tyrosine, etc., or taken together with X provides a functional group which may be used for linking, e.g., an olefin as in allyl or maleimidyl, dithio, etc.
The next peptide of interest, III (92), will be encoded by the region extending from about bp 972 to bp 1016 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X, wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 15 amino acids encoded by the LAV/HTLV III
genome.
The next peptide, IV (90), will be encoded by the region extending from about bp 1164 to bp 1250 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X, wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 29 amino acids encoded by the LAV/HTLV III
genome.
The peptide, V (88), will be encoded by the region extending from about bp 1278 to bp 1385 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X, wherein X and Y have been defined previously.
The next peptides of interest will be derived from the _q!2,2 protein region referred to as p18.
The next peptide of interest, VI (97), will be encoded by the region extending from about bp 450 through bp 545 and will have the following sequence,' where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X, wherein X and Y have been defined previously.
The next peptide of interest VII (71) will be encoded by the region extending from about bp 696 to bp 731. This peptide will include any oligopeptides coding for linear epitopes with the following amino acid sequence:
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr, wherein Y has been defined previously.
The next polypeptides of interest will be those derived from the env region, from gp110 (110kDa1).
The next peptide of interest, VIII, will be 5 encoded by the region extending from about bp 7246 through bp 7317 arid while coming within the general limitations indicated previously, will preferably have no more than 24 ami*no acids encoded by the LAV/HTLV III
genome.
10 The peptide of interest will generally have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X, where X is OH or NH2, wherein the carboxy terminal Z, e.g., Cys, if present, is an amino acid added to facilitate coupling of the peptide to a protein carrier.
Of particular interest is where 6, conveniently up to 4, of the naturally occurring C-terminal amino acids are deleted or substituted.
Oligopeptides contained within the above sequence of particular interest include:
(VIIIa) (49) Y-Arg-Val-Val-Gln-Ar.g-Glu-Lys-Arg-Z-X
(VIIIb) (50) Y-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-X.
The next peptides of interest will be derived from the env region known as gp4l.
The next peptide, IX (56), will be encoded by the region extending from about bp 7498 to bp 7554, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X, wherein X, Y and Z have been defined previously.
Uligopeptides contained within the above sequence of particular interest include:
(IXa) (56/39) Y-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X
and (IXb) (39/56) Y-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Z-X.
The next peptide of interest, X (39), will be encoded by the region from about bp 7516 through bp 7593 and has the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, where X is OH or NH2.
The next peptide, XI (40), will be encoded by the region extending from about'bp 7630 to 7689 where oligopeptides included within the following sequence will include linear epitopes within such sequence:
(XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X, wherein Y, X and Z have been defined previously.
The next peptide of interest, XII (23), will be encoded by the region extending from about bp 7708 through bp 7779. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
(XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X, wherein X, Y and Z have been defined previously.
The next peptide of interest, XIII (79), will be encoded by the region extending from about bp 7543 through bp 7593. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
(XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, wherein X and Y have been previously defined.
The next peptide of interest, XIIIa (78), will be encoded by the region extending from about bp 7561 through bp 7593. This peptide will include any oligopeptide coding for linear epitopes within the following amino acid sequence:
(XIIIa) (78) Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
Of particular interest is the use of the mercaptan group of cysteines or thioglycolic acids used for acylating terminal amino groups or the like for linking two of the peptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage. To achieve this, compounds may be employed having bis-haloacetyl groups, nitroarylhalides, or the like, where the reagents are specific for thio groups.
Thus, the linking between the two mercapto groups of the different peptides or oligopeptides may be a single bond or a linking group of at least two, usually at least four, and not more than about 16, usually not more than about 14 carbon atoms. Of particular interest, is where a member of a sequence from the c.ca region is linked to a member from the env region.
These chimeric peptides which may include non-amino acid linkages, may be further modified as will be described for the peptides and oligopeptides.
The subject peptides may be employed linked to a soluble macromolecular (e.g., a5kDa1) carrier.
Conveniently, the carrier may be a poly(amino acid), either naturally occurring or synthetic, to which antibodies are unlikely to be encountered in human serum. Illustrative polypeptides include poly-L-lysine, bovine serum albumin, keyhole limpet hemocyanin, bovine gamma globulin, etc. The choice is primarily one of convenience and availability.
With such conjugates, there will be at least one molecule of at least one subject peptide per macromolecule and not more than about 1 per 0.5kDa1, usually not more than about 1 per 2kDal of the macromolecule. One or more different peptides may be linked to the same macroniolecule.
The manner of linking is conventional, employing such reagents as P-maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid anhydride, glutaraldehyde, etc. The linkage may occur at the N-terminus, C-terminus or at a site intermediate the ends of the molecule. The subject peptide may be derivatized for linking, may be linked while bound to a support, or the like.
The compounds may be employed as labeled or unlabeled compounds depending upon their use. (By label is intended a molecule which provides, directly or indirectly, a detectable signal.) Various labels may be employed, such as radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates, cofactors or inhibitors, particles, e.g., magnetic particles, combinations of ligands and receptors, e.g., biotin and avidin, or the like. In addition, the peptides may be modified in a variety of ways for binding to a surface, e.g., microtiter plate, glass beads, chromatographic surface, e.g., paper, cellulose, silica gel, or the like. The particular manner in which the polypeptides are joined to another compound or surface is conventional and finds ample illustration in the literature. See, for example, U.S. Patent Nos.
4,371,515; 4,487,715; and patents cited therein.
Various assay protocols may be employed for detecting the presence of either antibodies to retroviral proteins or retroviral proteins themselves.
Of particular interest is using the peptide as the labeled reagent, where the label allows for a detectable signal, or binding the peptide, either directly or indirectly to a surface, where antibody to the peptide in the sample will become bound to the peptide on the surface. The presence of human antibody bound to the peptide can then be detected by employing a xenogeneic antibody specific for human immuno-globulin, normally both human IgM and IgG, or a labeled protein specific for immune complexes, e.g., Rf factor or S. aureus protein A.
Various heterogeneous protocols may be employed, either competitive or non-competitive.
Peptide may be bound to a surface or support ("support") and labeled antibody allowed to compete 5 with antibody in the sample for the limited amount of bound peptide. The amount of label bound to the support would be related to the amount of competitive antibody in the sample.
Antibody could be bound to the support and 10 the sample combined with labeled peptide. After contact of the reaction mixture with the bound antibody, the amount of label bound to the support would relate to the amount of cognate antibody in the sample.
15 Xenogeneic anti-human antibody, e.g., antibodies to the Fc of IgG and IgM (immunoglobulins), could be bound to a support. The sample would be contacted with the immunoglobulins and labeled peptide, whereby the amount of labeled peptide bound to the support would be indicative of the presence of the cognate antibodies.
Alternatively, homogeneous assays can be employed where the peptide is bound to an enzyme, fluorescer, or other label, where the binding of antibody to the peptide results in being able to discriminate between the label involved with a specific binding pair complex and label which is not involved in the complex. For assays involving such techniques, see for example U.S. Patent Nos. 3,817,837; 3,850,752;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074;
and 4,098,876.
As an illustration of the subject invention the subject peptides may be conjugated to a fluorescent molecule, such as fluorescein, rhodamine or umbelliferone. Various techniques may be used for detecting complex formation with antibodies, e.g., fluorescence polarization. In this assay the fluorescence polarization is different between complexed and uncomplexed peptide conjugate.
Apparatuses areavailable for measuring changes in fluorescence olarization e. TM
p , g., TDx supplied by Abbott Laboratories, Chicago, IL.
Illustrative of an assay technique is the use of sample containers, e.g., microtiter plate wells, where the subject polypeptides or conjugates thereof are adhered to the container bottom and/or walls either covalently or non-covalently. The sample, normally human blood or serum diluted in an appropriately buffered medium, is added to the container and a sufficient tinie allowed for complex formation between the polypeptide(s) and any cognate antibodies in the sample. The supernatant is removed and the container washed to remove non-specifically bound proteins.
A labeled specific binding protein which specifically binds to the complex is employed for detection. To the container may be added xenogeneic antisera to human immunoglobulin, particularly anti-(human IgM and IgG) in an appropriately buffered medium. The xenogeneic antisera will normally be labeled with a detectable label, e.g., radionuclide or enzyme. Instead of antisera, proteins specific for the immune complex may be employed, e.g., S. aureus protein A. The label may then be detected. For example, with an enzyme, after removal of non-specifically bound enzyme label, a developer solution is added. The developer solution will contain an enzyme substrate and possibly enzyme cofactors, chromogens, etc., which, upon reaction, provide a colored or fluorescent product which may be detected colorimetrically or fluorimetrically, respectively.
The peptides can be prepared in a wide variety of ways. The peptides, because of their relatively short size, may be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available today and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., 1984; and Tam et al., J. Am.
Chem. Soc. (1983) 105:6442.
Alternatively, hybrid DNA technology may be employed where a synthetic gene may be prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof, where the single strands overlap and can be brought together in an annealing medium so as to hybridize. The hybridized strands may then be ligated to form the complete gene and by choice of appropriate termini, the gene may be inserted into expression vectors, which are readily available today. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual, CSH, Cold Spring Harbor Laboratory, 1982. Or, the region of the viral genome coding for the peptide may be cloned by conventional recombinant DNA techniques and expressed (see Maniatis, supra).
DNA coding sequences which may be used for expressing peptides I - XIII are:
I (15) (TAT)GATTGTAAGACTATTTTAAAAGCATTGGGACCAG
CAGCTACACTAGAAGAAATGATGACAGCATGT
II (17) (TGT)TTAAAAGAGACCATCAATGAGGAAGCTGCAGAAT
GGGATAGAGTGCATCCAGTGCATGCA
III (92) GATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCA
GGCCAG
IV (90) TATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCA
AAAGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAA
ACTCTAAGA
V (88) AATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAAC
CCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCA
GCTACACTAGAAGAAATGATGACAGCATGT
VI (97) AGGGAGCTAGAACGATTCGCTGTTAATCCTGGCCTGTTA
GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTA
CAACCATCCCTTCAGACA
VII (71) GACACAGGACACAGCAGCCAGGTCAGCCAAAATTAC
VIII (36) GTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCA
AAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCA(TGT) IX (56) ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGA
TACCTAAAGGATCAACAG(TGT) X (39) AGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAG
CTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGC
XI (40) (TGT)AAATCTCTGGAACAGATTTGGAATAACATGACCT
GGATGGAGTGGGACAGAGAAATTAAC(TGT) XII (23) (TGT)CATTCCTTAATTGAAGAATCGCAAAACCAGCAAG
AAAAGAATGAACAAGAATTATTGGAATTAGATAAATGG
(GGA) XIII (79) AAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA
AAACTCATTTGC
Fragments from these sequences may be employed for expression of peptide fragments, conservative base changes can be made, where the modified codon(s) code for the same amino acid(s), or non-conservative changes in the coding sequence may be made, where the resulting amino acid may be a conservative or non-conservative change.
The coding sequence may be extended at either the 5'- or 3'-terminus or both termini to extend the peptide, while retaining its epitopic site. The extension may provide for an arm for linking, e.g., to a label, such as an enzyme, for joining two or all of the peptides together in the same chain, for providing antigenic activity, or the like.
For expression, the coding sequence will be provided with start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in a cellular host, e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.
The sequences by themselves, fragments thereof, or larger sequences, usually at least 15 bases, preferably at least 18 bases, may be used as probes for detectioii of retroviral RNA or proviral DNA.
Numerous techniques are described, such as the Grunstein-Hogness technique, Southern technique, Northern technique, dot-blot, improvements thereon, as well as other methodology. See, for example, WO 83/02277 and Berent et al., Biotechniques (1985) 3:208.
Conveniently, the polypeptides may be prepared as fused proteins, where the polypeptide may be the N- or C-terminus of the fused polypeptide. The resulting fused protein could be used directly by itself as the reagent or the subject polypeptide may be cleaved from all or a portion of the remaining sequence of the fused protein. With a polypeptide where there are no internal methionines, by introducing a methionine at the fusion site, the polypeptide may be cleaved employing cyanogen bromide. Where there is an internal methionine, it would be necessary to provide for a proteolytic cleavage site, e.g., poly-lysine and/or -arginine or combinations thereof, or the internal methionine could be substituted with an amino acid such as leucine and an N-terminal methionine added for cyanogen bromide cleavage. A wide variety of proteases, including dipeptidases, are well known and ;3 41 605 the appropriate processing signal could be introduced at the proper site. The processing signal may have tandem repeats so as to insure cleavage, since the presence of one or more extraneous amino acids will not 5 interfere with the utility of the subject polypeptides.
Depending upon the nature of the assay, the physiological sample, e.g., saliva, blood, plasma, or serum, may be pretreated by dilution into an assay medium, which will usually be an aqueous buffered 10 medium employing one of a variety of buffers, such as phosphate, tris, or the like. A preferred diluent is blotto (5% w/v nonfat dry milk, .01% thimerosal, .01%
Antifoam A in .01 M sodium phosphate, pH 7.2, and .15 M
NaCl). Usually the pH will be in the range of about 6 15 to 9. The sample will then be combined with the reagent in accordance with the appropriate protocol and sufficient time allowed for binding. Where a heterogeneous system is used, usually the stages will be followed by washes, to minimize non-specific 20 binding. At the end of the procedure, the label will be detected in accordance with conventional ways.
Besides the use of the subject peptides and their analogs in assays, the subject peptides may also find use by themselves or in combination in vaccines.
The peptides may be formulated in a convenient manner, generally at concentrations in the range of lug to 20mg/kg of host. Physiologically acceptable media may be used as carriers, such as sterile water, saline, phosphate buffered saline, and the like. Adjuvants may be employed, such as aluminum hydroxide gel, or the like. Administration may be by injection, e.g., intramuscularly, peritoneally, subcutaneously, intravenously, etc. Administration may be one or a plurality of times, usually at one to four week intervals.
The following examples are offered by way of illustration and not by way of limitation.
EXPERIMENTAL
Peptides 15, 71, 88, 90, 92 and 97 were assembled on a t-butyloxycarbonyl (BOC)-methylbenzyl-cysteine-phenyl-acetamidomethyl (PAM) polystyrene/di-vinylbenzene resin (Applied Biosystems, Inc., Foster City, CA). For carboxamide peptides 78 and 79 p-methylbenzhydrylamine polystyrene/divinylbenzene was used. Symmetrical anhydride couplings were carried out in an Applied Biosystems 430A synthesizer, except that glutamine and asparagine were coupled as hydroxybenzo-triazole esters. Benzyl based side chain protection and BOC alpha-amine protection were used. Tryptophan was protected by the formyl moiety, methionine was protected by its sulfoxide, and dinitrophenol was used for protecting histidine. Protecting groups were removed by conventional procedures.
Peptide 36 was assembled on a benzhydrylamine polystyrene/divinylbenzene resin in a Beckman 990 peptide synthesizer (Beckman Instruments, La Brea, CA).
Benzyl based side chain protection and BOC alpha-amine protection were used. All the residues were added by the direct dicyclohexylcarbodiimide method, except for glutamine which was coupled as the hydroxybenzotriazole ester.
Peptide 39 was synthesized on a benzhydryl-amine resin as described for peptide 36 with asparagine also being coupled as the ester.
When the peptides were radiolabeled, it was by acetylating the amino terminus with 3H-acetic acid and an excess of dicyclohexylcarbodiimide.
The peptides were deprotected and cleaved from the resin by the Tam "low-high" HF protocol (Tam et al., supra). Peptides 36, 39, 79, 78, 88, 90, 92 and 97 were extracted from the resin in 5% acetic acid and subjected to gel filtration chromatography in 5%
acetic acid. Peptides 15 and 71 were extracted in 0.5M
ammonium carbonate/0.OO1M dithiothreitol (DTT) and chromatographed in 0.05M ammonium carbonate/0.005M
B-mercaptoethanol. Fractions containing the peptide were pooled and lyophilized. The integrity of the synthetic products was assured by ninhydrin monitoring after each coupling and by analytical reverse phase chromatography and amino acid analysis.
Peptides 90, 92 and 97 were polymerized by oxidation of their sulfhydryls to intermolecular disulfides. Briefly, the lyophilized reduced peptide was dissolved in minimal 6M guanidine HC1/0.1M sodium phosphate, pH 9.0, and allowed to oxidize overnight at room temperature.
Peptides 15, 23, 36, 40, 49, 50 and 56 synthesized above were conjugated to bovine serum albumin (BSA) which had been derivatized with N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), essentially as described by Ishikawa et al., J. of Immunoassay (1983) 4:209.
To 2m1 of a BSA solution (20mg/ml in 0.1M
potassium phosphate, pH 7.0) at 30 C was added 1.5m1 of an SMCC solution (8mg/ml in dimethylformamide). The mixture was stirred magnetically for lhr, after which it was centrifuged to remove any precipitated albumin.
The clarified mixture was then subjected to gel filtra-tion on SephadexxG-25 equilibrated in O.1M potassium phosphate, pH 6Ø The protein-containing fractions, as determined by their absorbance at 280nm, were pooled and stored frozen at -70 C until needed.
The peptides synthesized above were dissolved in 0.1M sodium phosphate, pH 8.0 to a concentration of 5mg/ml (peptide 36), 8mg/ml (peptide 15) or 1.6mg/ml (peptide 39). To 1.5m1 of each solution was added 2mg of solid DTT. The solutions were stirred for 30min at 30 C, after which they were subjected to gel filtration chromatography on Sephadex G-10, equilibrated in 0.1M
potassium phosphate, pH 6Ø The tritium-containing fractions, as determined by scintillography of aliquots, were pooled and mixed with lml (0.5m1 for * Trade Mark peptide V) of SMCC-derivatized BSA. The resultant mixtures were stirred at 30 C for 12hr and then dialyzed exhaustively against water.
The other peptides were prepared in accordance with the procedures described above and conjugated to BSA in accordance with the above described procedures. The ratio of peptide to BSA was determined by employing radiotracers in accordance with conventional ways.
mols peptide mol BSA
I (15) 14 II (17) 5 VIII (36) 9 IX (56) 17 X (39) 6 XI (40) 18 XII (23) 30 *
* may be erroneous and could be as high as 55.
Analysis by ELISA
The lyophilized peptide or protein/peptide conjugate was dissolved in 6M guanidine HC1. The guanidine solutions were diluted in 0.05M
carbonate/bicarbonate buffer (pH 9.6) to a final peptide concentration of 8 to 40ug/ml just prior to plating in the 96-well plates. Fifty ul of peptide solution were aliquoted per microtiter well and incubated at 4 C overnight. Plates were then blocked with BLOTTO (5% [w/v] nonfat dry milk/0.01$
thimerosal/0.01% antifoam A in 0.O1M sodium phosphate, pH 7.2/0.15M sodium chloride) for one hour at 37 C.
Sera were diluted 1:100 with a 1:1 mixture of BLOTTO
and PBS (0.O1M sodium phosphate, pH 7.3/0.15M NaCl), and 50u1 of diluted sera was added to each well and incubated for one hour at 37 C. The sera were removed and the plates were washed three times in wash buffer (0.15M NaCl/0.05% (w/v) Tween 20) before adding 100u1 of the goat anti-human IgG/horseradish peroxidase conjugate (50% stock diluted 1:10,000 in 50mM sodium citrate/0.05$ Tween 20/1% heat-inactivated normal goat serum; obtained from Antibodies, Inc., Davis, CA) for one hour at 37 C. The conjugate was removed and the plates washed three times with 0.15M NaCl/0.05$ (w/v) Tween 20* The ELISA was developed by adding 100u1 per well of substrate solution (10mg 3,3',5,5'-tetramethylbenzidine in 50m1 0.05M sodium citrate, pH 7.0) for 30min at room temperature.
Reactions were stopped with 100u1 per well of 3N H2SO4-and the optical density at 450nm determined by an automated ELISA reader.
Summary of Table 1 Table 1 gives ELISA results for all petpides that are immunoreactive.
Peptides 49 and 50 are part of peptide 36.
Peptide 56 partially overlaps peptide 39.
Peptide 49-BSA reactive with 10/10 positve sera; not reactive with 2/2 negative sera.
Peptide 50-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 56-BSA reactive with 10/10 positive sera; not reactive wtih 2/2 negative sera.
Peptide 40-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 23-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 15-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 36-BSA reactive with 9/10 positive sera; not reactive with 2/2 negative-sera.
In a larger panel, peptide 56 which partially overlaps peptide 39, is not reactive with all sera that are reactive with peptide 39. This suggests that there * Trade Mark are at least two reactive epitopes within peptide 39 or that peptides 39 and 56 contain non overlapping reactive epitopes.
Peptide 23 (both conjugated to BSA and 5 unconjugated) was further tested against a larger panel of sera (23 positives, 8 negatives) and displays a sensitivity of 80-90%.
Summary of Table 2 10 Table 2 shows that two of the peptides derived from the cag region (#15 and #17) are reactive with LAV seropositive sera that are poorly reactive or unreactive with peptide 39. This supports the use of a combination of _qa2 and env peptides to produce a more 15 sensitive assay.
Summary of Table 3 Table 3 compares results obtained with peptides 15-BSA and 39 with results obtained with these 20 peptides physically mixed (15-BSA + 39) or chemically combined (thiol-oxidized 15 + 39).
The result obtained when positive samples are assayed with either the physical or chemical combination of peptides 15 and 39 is generally higher 25 than that obtained with either peptide alone. This is clearly demonstrated with samples 126, 131, 135, 138 and 1296.
Summary of Table 4 Table 4 compares results obtained with peptides 71, 78, 79, 88, 90, 92 and 97 in an ELISA
assay. All of the peptides except one provide better than 70% correlation for positives and two peptides had 100% correlation.
~
N r 1~ t0 = 01 J CO N Q1 ~ ~
N O O zt Vl N l!1 %O tP1M N
'~-. =.. p~ U1 V1 1~ O O O
d = = ~ Z r G. O N O O r O ~ O O O O
1 a ~ ~O P N O h r vl P Pf %D
N ~O r p~ O ~O f~ O~ O Yf O N N
m ^ N O N ^ .+ O O O
I O ~O h Qf O ~O e'- W Yf N V Yf < ~O =? h N N vl h N ~D N
N . = = . . ~
CO O r O ~ r r O O r ~ O O O
1 1~ v Q N h 1~ N f~ N 1~ V Lfl y ~D O ~O ~O ~O Pf N
m ^ ='= O O r N ^ N N ~ O O
P rf ^ ~O a0 Ot ~f %O vf N u1 EO
~O n t'f O r r= N a n o In o a ~o .o eo M ~ O o Q ^ ^ o o r r r r r o za _ ~ O 1 1~ O n {O O%
N N N N O ^ ~
W E'~ N ~O N f7 N Hf 61 ^ N C. O O O O O r N O O
,'+ F--1 1 Lff fp9 < O~ N ~ O ^ ~ /=Caf OI N N
a OA N O~ PI N v N 1~ O O
O ^ O O O O r O r r O d ~ .7 F=1 (V 7H.r 1 P. ~O Yf tO 1, N O ~ N
1-4 Q~ N ~O ~t ~n N N ~
> n In wl o W W m ^ ^ o 0 0 0 0 0 ^ r o 0 p~ u- o~ ao u- .. a P. %o o% v m a O N Lf! /'f Ff Yi A ~
1 N ~ < f9 r ^ r r m O r O O O O O O N N O O j Qi E"1 ~=
U ul~v .+
N
H H p r H W p v o N H1 V- Y- H VI N YI N M p v L
TL 61 Oi 07 N 61 N di 6) 61 01 = O 01 ?. ~ -N 2*t v+
A E-~ 0 H v Ha 44 OI a Ot N O O O O OI O
cp = N
W > O CO O uf N v) O
r'1 N N O O ~ O
O f/~ < Y .= r r r = = ~ .
(!~ Nr r r N ^ N r C O
o d ~ ~
cn d W
t1 Cry r r ~7C H - L r L r L r L r L r L r L r L r_ L r L r O b Q= ~õ~ O i6 Of0 0 0 4 O q O 4 O A O16 O A O q X X
~ W \ 7 \ 7 \~ \ 7 \ 7 \ O \ 7 \ 7 X p \ 7 \ O Y C-p X p X p X p X p X p x p X p X X ~ N N. vl A Np 4 QVI i0 VQI N QVI W Yf t! Vf A N N N C N A{11 ~ V L ~ O
bN A~
U ~ < O < O < O < O < ~ < I < < 01 Y 0! 3!
J L J t J t J t J L J L J t J C J L J t S L = t .-~
O
--~ ~ N V O f7 r a N
~ ~ ~ ^ ^ r r .~ ... ^ 1 O O O N
E 1 ~p > ci N ~p r ~ N Y1 N V' L1 r p ~+1 N O O
O N O O O O O
N V O~ ~D N O~ %D
1 ~O O R N O
J O N O O r O O
Q'.
',zõ~ H 1 \O Or ~O N P N N
tn O O O O O O O
rn w M H
t~ A
H~ Hz o W 6 ~ w N m a w o v ;X4 H ~ o ~ O u H
v~ H
W U
A W '"
H H ~~
W p r o ~ r O O N
O r O = O N ~
O r r ~ N O O
0 a A
`vx vx \x a~~N !" ~
O U] ~ CY CY C W i0 LO
0 Nmp Atpn i0appp ~Y ~~
C ocAL J.G JL Sr St UO W 5 r Ot V ^ ^ O~
~, p01 O N gfl ~ N
y N y~ r ~ ~O ~O
oa o" z M p o H Q~
A F N
U v F x ~ WA 0 ~ e~v, v o~ ~ ~
M ao v o ~ v v ~
r = . ^
Cn W 0 r N ~ O r r r C N O C G p p Wx F
A F
F C~i N o~ ~o v ~ ~ ~ t ' ~ N
N O~ ~ p W W N A w r r C C C C A C. C O O C.
a m :21 Fcn 1-4 Cn N
.'3' Q~i 0 ~O Mf ~q PI r'f ~ ~.Nj ~ 0 < V N
O O
O ^ O r ^ ^ O O O O o a ~n H
00 W ^
N A 7r~ 1 . ~ N ~ ~ ~ N ~ 10 ~O O ~ ~ ED
> 42 C2, 0 O O O C. p ^ = . , , O O O
O O
z H N
I ~
A
O~ W L> LO > o> L>
M Z 9 Or Or dr ~q N N N N y" Nr ~=r N~
~ ~ m d m m d ai oo 00 00 00 c~ O c ca ca cn CO.
u) cn a A H ¾ a H~a ~^ o 0 o N o _ W x O 14 O m ~ ~
~ N f7 M O ~ ra'1 O O N
a U F r ^ r . O , _ N o 0 " r ly '=, r .
O O W N N O O= O O
H
a ~ r r r r cn t=a W L r L r L r L r L r L r L r L q b q ~0 H Q~ H O q O~0 010 0 0 O O O q L r p4 C=~ E..~= \7 \3 \7 \~ \Z \, 0 7 0 ~ G 0 01 x x X01 X Y
~X oX V% laX OX 9X
C Y C O C Y C O C Y C 01 C 01 ~ ~ H ~ N ~ N ~ u-~0 N r0 M A N ~0 N A N i0 N
QQpQ ~O H i0 N 0 9 a.~ 0 ar L a+ L ~r L
C) G4 E E E E QE Eo N oE C O =r 01 r 01 r N r 01 f0 ar < < O NO ~ O N V ~ O < < a ~ ~0 a,+ ~0 s+ 10 a~
V a 0 J t J t J Z J l J Z J t J~ J= SC m S t S L S L S t N
(z~ ~ ^ ^ ^ ~ ~ ^ uNf P. ~ o~i ~ P. n a = AD ^ kO %D %o ~D
H
V
m N
v _ ~ 1~ !V ~O P- N
X N O ~ O% P1 Y7 S~ 'O 16 .6 N 01 O = =
1 ~ N C N C C ~ C C C C ~ ~
r O
t`
O O O O
v v v v v v N N N N N N N N
A A C A A C C A G C C C A A
M
O N do %O in r !V N N N b ~
rf e'1 N ~ O Yf Uf Yf O O N
O ~- ~- O -O ~
1'9 O N N O e1 N ~ r N ~ ~ o 0 o e o 0 0 0 0 0 0 0 N
q N N N N N N N M N N tl1 N N N
GGG Yf Y1 ~1 ~1 !~ ~ ~s ~ !~ ~ ~ ~1 >1 C
O
u N
L~
O, O O f'1 Pf Qt N Nf 1D p .- N O h > O O V' 10 O 4) 1-~ PI '? RI O N N
r O N ~ N N N O
m O Q~ N N
N. .
- O
.
r L r L r L r L r L r L r L r L r L r L r 0 O r L.
~ d \ O q O q O~0 o A O q O q O q O N O A O~tl O~0 >r >r CX Vx 9X ~7~t ~x 9x ax oX ~X ~X ~x Vx =rl 0 +-o qm cm em cm cm cm cJI cm Cm Cm Cm Cm +~ L N L. YI i0 N i0 N i0 N q N q N /6 N ~b N O N N N '0 N A N
rNC ~~ A pE pE QE QE QE QE QE pE QE
O O Q O O < 8 < 6 < O < O < < < < O <~ < O < d <
C) d Y d Y J t J L J t J t J t J t J L J L J t J t -J L J t M V O N ~ YI 1p P {b Ct O N
L O 1 O N N N N N N N N N Pf NI NI
W N vf ~= V r .. ~ .-. ~ ~ .- .- ~ r- ~
aa N
x 9 O C O O O
O
0 C= 0 0 ^ a M Ln Y1 an - ~ O
O ~ o 0 C. 0 n a 'r` C C C
%. C
C
O
V
~
T N
! O%
~ 40 C C C
O
r ~ r .d r O '0 '0 i0 7 7 7 x x x rO LO LO
~ N L M L a+ L y L
~ '- CI r O r ~i r d1 Q Y d1 {b/ m d Y m Y
U xt xt St rL
N p ly %O O1 O1 O1 W Y `p ao cc ao cC
H
1 1 O CO N=-+ m 00 m %~o L+'1 %O 01, u'1 N M 7=--~ %D L/1 %O ~,o O M u'1 N O M
a0 1 N M rn a0 N rr .4 .7 O~Y M O Q~ M .-~ O--+ 00 r- Lr1 J611 ao N t- r- I O
t~ 1 u'1~70N.i.-~ Z NN.--~O. NOZO0000~00 I N r=+
I . . . . . . . . . . . . . . . . . . . . 1 . \
I O %D I
(~!] j ~A p~p ~p -.:r %D ,--4 M -,Y N%O ~t ID tV (- O 00 N --,T ~7 N M O %O N
M I
V) O~ I -.7 O 00 ~,O -zr ~ CG cO1 00 ID -:T 00 00 =-+ m Ln "O I-O N 1- N. u'1 -T N~O 00 I O 00 C', f~ 1 C1 0p O N=--~ M m OZ Ln ~--~ u"1 O c'n M u1 --I 1- Lf'1 Z cV --1--4.-+ N.--~ ,-+ 1 M =-+
1 . . . . . . . . . . . . . . . . 1 . \
d i N.~ N.-~ .-~ ~ I O o0 V) I I
H I I
a ~O O--1 %.O %O Lr1 N O u1 %0 N 1~ 00 L/1 N 00 =--~ ~ oO O-4 ON O vl O( r+ 1 t- un ~ .., -1 M M Ln -4 00 cn .p O Orn o0 r+ 00 7 A A O 00 O% N.G 0 00 1.- 1 0 00 .7..~ n 1 ~t fll tr1 -.T NV1 N M N-4 Vl M M N1 N M.--4 M',Z, Z r+ O O-4 ~--~ -4 O O I N ~--~
Q I , . 1 . \
1 1 O ~
I I "a z I I
po 1 00 . - 4 NUr1 t- L!1 O u'1 I : r O-+ 1~0 ON -4 ~O N cM N-7 O vl Wl O r=+
N I
r- r- I Lf1 ~t O O% r, v1 cY1 00 1.0 oo N NO'~ ON O N~Y Vl A A~D r- ON - u1 N
u1 N I O 00 O, u'1 C~1 M M M~T N i~ M O~ 1O N M M N f~ N',~ z.--~ =--~ ~~--4 ~~ I fV ~
'p I . . . . . . . . . . . . . . . . . . . . . . . . I . \
V 1 N N N = N~ ~~ =--~ = N I 0 00 tC '~
I I
r, I O N N ao =+ 00 r- O~o 00 N O~o N M n ao 00 %.O -=+ oo N O-4 00 M I
00 1 =-i =-r t- ON OLr1 Ln 00 v1 Lr1 17 rY t` N A~T O% u'1 A N O M N rn Orn -O% oo 1 O 00 ao 11,0 O% Mr- (N M.-~.-+cNOM r- t-~7 Z ^~--~0 z00- 0 0 1 cV ~+
~ I \
1\ I .-i ~ . ~ . . . . . . . . ~ . . . N N . . . . . . . I O cn ri 1 M I I '-"
I
r~ Q 1 O+ a .o O ir1 ~o N m - . T O MU.1 % O ~--~ ;r m Lf'1 O% .-r Oo M f- m - - T
O1% u1 O-+ i vl O t, 00 O0 L!1 -.t Ln N 7 CM c*1 00 O m M.7 ON A O.-y - 1- %C ui %O N O oD
w0 0% N rn cl1 00 =-4 %D =-~ ~o 00 0~ O N C. 1~ a0 O Z Z~O ~o u) ~7 M~Y V1 ~1 t~ =-+
~ E 4 . . ~ ~ . . . ~ . . . . . . . . I O V1 U) 1 I ""
ww 1 1 a%A 1~--4 0 u"1%CN.-+Odo OoC00~nO~DON N.--i v10oN.-40~.71-Q N 1 0 cNONNC=1NM0--+Ln Ln 0 o00 ~r- mr- tncocor- Lnr- I O 00 wpq O~ 1 N N ~ r+ '~ r+r+ ~--~0=-+~"7O:G OOOOOOOO ~--~ =-+
N H 1 . . . . . . . . . . . . . . . . . . . . . . . . . . I . \
oN Hz i O
tA 6 I I ~
W I I
Afj+ 1 I
N O I I
H
048 u) a~ l wo ~a a I I
a ~-+ =r+ 1 I
H 'b " I
L*a U 41 =H 1 I N N 7 O W 6 m 1 tn m cn m cn cn (n (D m cn w u) tn m w (n ED rn m v) 1 6 r1 =~
H !+ o I N N Gl G1 C1 C- Cl N Ol GJ C- Gl N C- U1 Gl G/ N N Cl o 0 0 0 0 0 0 o I ~+ a+~
z w =r1 a 7, 7+ D+ >1 >+ D+ 71 71 7, >, 7~ 7, f. R~~~ G 1/. G I rl ~ r1 oA wo I
U) p 1,,, I i G cn o ~-4W o v 1 i 0 w dEx~ U~ I
4-4 ~ a U f=+ I
. ~ i G-0 . u w ,I G
o I 1 w " o Ol Z I 1 o u H a.+
I r- O'T Ln oo ~t Ln M--T Ln 1- 0 -4 ao cn .-4 .-~ Orn a+ .-4 r1 -11 I'D I+1 Cd N Gl W ~ 1 N M N N N M('M LP1 ul u1 Lf1 fV N M t=1 l+l fYl O CV ~ M .-I ln -7 ~ ~r-+ ( 7 Y+ U) .-4 -, . . 4 . -4 .-4 .-1 .-r .-4 u') .-, >+ z Z Z ~o %o Z Z Z U t*+
a- I I
E~-~ ~n I I
Prepared as described in U.K. application Serial No. 83/24800, filed September 15, 1983.
Radiolabeled LAV antigens were disrupted in R1PA buffer (Gilead et al., Nature (1976) 264:263) and then were reacted with human serum. The resultant immune complexes were separated by binding to a Staphylococcus aureus adsorbent (Kessler, J. Immunology (1975) 115:1617) followed by multiple washings.
Immuneprecipitated antigens were analyzed by SDS polyacrylamide gel electrophoresis (Laemmli, Nature (1970) 227:680) followed by fluorography. Presence of either a p25 or gp43 band was considered necessary and sufficient to confirm a sample as seropositive.
Immuneprecipitated antigens were analyzed by SDS polyacrylamide gel electrophoresis (Laemmli, Nature (1970) 227:680) followed by fluorography. Presence of either a p25 or gp43 band was considered necessary and sufficient to confirm a sample as seropositive.
3 LAS = lymphadenopathy syndrome.
4 N.D. = not determined.
It is evident from the foregoing results that by employing one or a combination of peptides of the subject invention, a sensitive accurate test for the presence of antibodies to AIDS is provided. The subject peptides can be used by themselves or in combination with a screening assay or confirmatory assay, where the complete lysate or complete antigens may be employed as an independent procedure. Further-more, because of the specificities of the peptides, one would anticipate that the DNA sequences coding for the peptides would also find similar specificity in a DNA
hybridization assay. Thus, the subject invention allows for the detection of patients who have been exposed to the retroviral etiologic agent of lymph-adenopathy syndrome and/or AIDS.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications 33 =
may be practiced within the scope of the appended claims.
It is evident from the foregoing results that by employing one or a combination of peptides of the subject invention, a sensitive accurate test for the presence of antibodies to AIDS is provided. The subject peptides can be used by themselves or in combination with a screening assay or confirmatory assay, where the complete lysate or complete antigens may be employed as an independent procedure. Further-more, because of the specificities of the peptides, one would anticipate that the DNA sequences coding for the peptides would also find similar specificity in a DNA
hybridization assay. Thus, the subject invention allows for the detection of patients who have been exposed to the retroviral etiologic agent of lymph-adenopathy syndrome and/or AIDS.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications 33 =
may be practiced within the scope of the appended claims.
Claims (64)
1. A peptide of the formula:
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated I, or I linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated I, or I linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
2. A peptide of the formula:
(II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-Z-X (from the gag p25 protein sequence) where X is OH or NH2, and Y and Z, if present, are an amino acid added to facilitate coupling, provided that Y is not Met, N-terminal acetylated II, or II linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-Z-X (from the gag p25 protein sequence) where X is OH or NH2, and Y and Z, if present, are an amino acid added to facilitate coupling, provided that Y is not Met, N-terminal acetylated II, or II linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
3. A peptide of the formula:
(III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated III, or III linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated III, or III linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
4. A peptide of the formula:
(IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X (from the gag p25 protein sequence) where X is OH or NH2, and Y and Z, if present, are amino acids added to facilitate coupling, N-terminal acetylated IV, or IV linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X (from the gag p25 protein sequence) where X is OH or NH2, and Y and Z, if present, are amino acids added to facilitate coupling, N-terminal acetylated IV, or IV linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
5. A peptide of the formula:
(V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated V, or V linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X (from the gag p25 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated V, or V linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
6. A peptide of the formula:
(VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X
(from the gag p18 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VI, or VI linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X
(from the gag p18 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VI, or VI linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
7. A peptide of the formula:
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr (from the gag p18 protein sequence) where Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VII, or VII
linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr (from the gag p18 protein sequence) where Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VII, or VII
linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
8. A peptide of the formula:
(VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X
(from the env gp110 protein sequence) where X is OH or NH2, and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VIII, or VIII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X
(from the env gp110 protein sequence) where X is OH or NH2, and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated VIII, or VIII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
9. A peptide of the formula:
(IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X
(from the env gp41 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated IX, or IX linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X
(from the env gp41 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated IX, or IX linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
10. A peptide of the formula:
(X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X is OH or NH2, N-terminal acetylated X, or X
linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X is OH or NH2, N-terminal acetylated X, or X
linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
11. A peptide of the formula:
(XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X (from the env gp41 protein sequence) where X is OH or NH,, and each of Y and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XI, and XI linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X (from the env gp41 protein sequence) where X is OH or NH,, and each of Y and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XI, and XI linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
12. A peptide of the formula:
(XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X (from the env gp41 protein sequence) where X is OH or NH2, and each of Y and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XII, or XII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X (from the env gp41 protein sequence) where X is OH or NH2, and each of Y and Z, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XII, or XII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
13. A peptide of the formula:
(XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XIII, or XIII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
(XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X is OH or NH2, and Y, if present, is an amino acid added to facilitate coupling, N-terminal acetylated XIII, or XIII linked to a peptide or protein of at least 5,000 molecular weight, which peptide or protein does not normally bind to antibodies present in a human host.
14. A vaccine composition comprising a physiologically acceptable carrier and at least one peptide of the peptides:
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X (from the gag p25 protein sequence) (II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-Z-X (from the gag p25 protein sequence) (III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X (from the gag p25 protein sequence) (IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X (from the gag p25 protein sequence) (V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X (from the gag p25 protein sequence) (VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X
(from the gag p18 protein sequence).
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr (from the gag p18 protein sequence) (VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X
(from the env gp110 protein sequence) (IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gin-Z-X
(from the env gp41 protein sequence) (X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) (XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X (from the env gp4l protein sequence) (XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X (from the env gp41 protein sequence) (XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X, when present, is OH or NH2, and each of Y
and Z, if present, are amino acids added to facilitate coupling, provided Y is not Met in peptide (II) (17), or said peptides conjugated to an immunogenic protein, said peptides or conjugates being present in an amount to provide an immunogenic response in a physiologically acceptable carrier.
(I) (15) Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X (from the gag p25 protein sequence) (II) (17) Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-Z-X (from the gag p25 protein sequence) (III) (92) Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X (from the gag p25 protein sequence) (IV) (90) Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Phe-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X (from the gag p25 protein sequence) (V) (88) Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-Ala-Cys-X (from the gag p25 protein sequence) (VI) (97) Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X
(from the gag p18 protein sequence).
(VII) (71) Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr (from the gag p18 protein sequence) (VIII) (36) Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X
(from the env gp110 protein sequence) (IX) (56) Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gin-Z-X
(from the env gp41 protein sequence) (X) (39) Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) (XI) (40) Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X (from the env gp4l protein sequence) (XII) (23) Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X (from the env gp41 protein sequence) (XIII) (79) Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X (from the env gp41 protein sequence) where X, when present, is OH or NH2, and each of Y
and Z, if present, are amino acids added to facilitate coupling, provided Y is not Met in peptide (II) (17), or said peptides conjugated to an immunogenic protein, said peptides or conjugates being present in an amount to provide an immunogenic response in a physiologically acceptable carrier.
15. A vaccine according to claim 14, wherein said peptides are coupled to immunogenic proteins.
16. A vaccine according to claim 14 or claim 15, wherein at least one peptide is one of I to VII (derived from the gag protein sequence) and at least one peptide is one of VIII to XIII (derived from the env protein sequence).
17. A vaccine according to any of claims 14, 15 and 16, wherein said immunogenic protein is tetanus toxoid.
18. A peptide according to anyone of claims 1 to 13, wherein the peptide is bound to a solid surface.
19. A peptide according to claim 18, wherein the peptide is conjugated to a water soluble carrier protein of at least 5kDal.
20. A method of detecting the presence of LAV/HTLV-III
virus or antibody to LAV/HTLV-III virus where a sample is combined with a protein composition having epitopic sites immunologically competitive with LAV/HTLV-III epitopic sites, whereby antibodies bind to said protein composition to form a specific binding pair complex and the amount of complex formation is determined, characterized by:
employing in the assay medium as a reagent said protein composition containing at least two peptides, one encoded in the region bp 1320 to bp 1385 (from the gag region) and the other encoded in the region bp 7231 to bp 7794 (from the env region).
virus or antibody to LAV/HTLV-III virus where a sample is combined with a protein composition having epitopic sites immunologically competitive with LAV/HTLV-III epitopic sites, whereby antibodies bind to said protein composition to form a specific binding pair complex and the amount of complex formation is determined, characterized by:
employing in the assay medium as a reagent said protein composition containing at least two peptides, one encoded in the region bp 1320 to bp 1385 (from the gag region) and the other encoded in the region bp 7231 to bp 7794 (from the env region).
21. A method according to claim 20, where each determination is made individually for the binding to each of the peptides.
22. A method of detecting the presence of LAV/HTLV-III
virus or antibody to LAV/HTLV-III virus where a sample is combined with a composition having epitopic sites immunologically competitive with LAV/HTLV-III epitopic sites, whereby antibodies bind to such protein composition to form a specific binding pair complex and the amount of complex formation is determined, characterized by:
employing in the assay medium as a reagent a composition containing at least one peptide which is a variant, by conservative or non-conservative substitution, of a peptide as specified in claims 1 to 13, the variant being immunologically competitive with a native LAV/HTLV-III virus protein.
virus or antibody to LAV/HTLV-III virus where a sample is combined with a composition having epitopic sites immunologically competitive with LAV/HTLV-III epitopic sites, whereby antibodies bind to such protein composition to form a specific binding pair complex and the amount of complex formation is determined, characterized by:
employing in the assay medium as a reagent a composition containing at least one peptide which is a variant, by conservative or non-conservative substitution, of a peptide as specified in claims 1 to 13, the variant being immunologically competitive with a native LAV/HTLV-III virus protein.
23. A peptide which contains up to 26 amino acid residues and includes the following amino acid sequence:
Arg - Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp -Gln - Gin -Leu - Leu - Gly - Ile -Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
Arg - Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp -Gln - Gin -Leu - Leu - Gly - Ile -Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
24. A peptide which contains up to 19 amino acid residues and includes the following amino acid sequence:
Arg- Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp and the pharmaceutically or diagnostically acceptable salts thereof.
Arg- Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp and the pharmaceutically or diagnostically acceptable salts thereof.
25. A peptide which contains up to 17 amino acid residues and includes the following amino acid sequence:
Lys - Asp - Gln - Gln - Leu - Leu - Gly - Ile - Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
Lys - Asp - Gln - Gln - Leu - Leu - Gly - Ile - Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
26. A peptide which is immunoreactive with antibodies to HTLV-III, HIV or AIDS
virus, contains up to 17 amino acid residues and includes the following amino acid sequence:
Lys - Asp - Gln - Gln - Leu - Leu - Gly - Ile and the pharmaceutically or diagnostically acceptable salts thereof.
virus, contains up to 17 amino acid residues and includes the following amino acid sequence:
Lys - Asp - Gln - Gln - Leu - Leu - Gly - Ile and the pharmaceutically or diagnostically acceptable salts thereof.
27. A peptide which is immunoreactive with antibodies to HTLV-III, HIV or AIDS
virus, contains from 6 to 17 amino acid residues and includes the following amino acid sequence:
Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
virus, contains from 6 to 17 amino acid residues and includes the following amino acid sequence:
Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
28. A peptide of claim 23 which is bound to a solid surface.
29. A peptide of claim 24 which is bound to a solid surface.
30. A peptide of claim 25 which is bound to a solid surface.
31. A peptide of claim 26 which is bound to a solid surface.
32. A peptide of claim 27 which is bound to a solid surface.
33. A peptide of claim 23 which is conjugated to a carrier protein or a carrier peptide.
34. A peptide of claim 24 which is conjugated to a carrier protein or a carrier peptide.
35. A peptide of claim 25 which is conjugated to a carrier protein or a carrier peptide.
36. A peptide of claim 26 which is conjugated to a carrier protein or a carrier peptide.
37. A peptide of claim 27 which is conjugated to a carrier protein or a carrier peptide.
38. A composition comprising a peptide of claim 23 together with a pharmaceutically or diagnostically acceptable carrier.
39. A composition comprising a peptide of claim 24 together with a pharmaceutically or diagnostically acceptable carrier.
40. A composition comprising a peptide of claim 25 together with a pharmaceutically or diagnostically acceptable carrier.
41. A composition comprising a peptide of claim 26 together with a pharmaceutically or diagnostically acceptable carrier.
42. A composition comprising a peptide of claim 27 together with a pharmaceutically or diagnostically acceptable carrier.
43. A vaccine composition comprising a peptide of claim 23 together with a physiologically acceptable carrier.
44. A vaccine composition comprising a peptide of claim 24 together with a physiologically acceptable carrier.
45. A vaccine composition comprising a peptide of claim 25 together with a physiologically acceptable carrier.
46. A vaccine composition comprising a peptide of claim 26 together with a physiologically acceptable carrier.
47. A vaccine composition comprising a peptide of claim 27 together with a physiologically acceptable carrier.
48. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of claim 23, (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
(a) providing at least one peptide of claim 23, (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
49. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of claim 24 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
(a) providing at least one peptide of claim 24 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
50. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of claim 25 (b)contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
(a) providing at least one peptide of claim 25 (b)contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
51. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of claim 26 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
(a) providing at least one peptide of claim 26 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
52. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of claim 27 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
(a) providing at least one peptide of claim 27 (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide - antibody complex is formed, (c) detecting the presence of said peptide - antibody complex.
53. A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 23 which is bonded to the solid support.
(a) a container (b) a solid support (c) a peptide of claim 23 which is bonded to the solid support.
54. A test kit for detecting antibodies to HIV-III, HIV, or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 24 which is bonded to the solid support.
(a) a container (b) a solid support (c) a peptide of claim 24 which is bonded to the solid support.
55. A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 25 which is bonded to the solid support.
(a) a container (b) a solid support (c) a peptide of claim 25 which is bonded to the solid support.
56. A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 26 which is bonded to the solid support.
(a) a container (b) a solid support (c) a peptide of claim 26 which is bonded to the solid support.
57. A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 27 which is bonded to the solid support.
(a) a container (b) a solid support (c) a peptide of claim 27 which is bonded to the solid support.
58. A peptide having specific immunoreactivity to antibodies to HTLV-III, HIV
or AIDS
virus which contains the following amino acid sequence:
Arg - Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp -Gln - Gln -Leu - Leu - Gly - Ile -Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
or AIDS
virus which contains the following amino acid sequence:
Arg - Ile - Leu - Ala - Val - Glu - Arg - Tyr - Leu - Lys - Asp -Gln - Gln -Leu - Leu - Gly - Ile -Trp - Gly - Cys - Ser and the pharmaceutically or diagnostically acceptable salts thereof.
59. A peptide of claim, 58 which is bound to a solid surface.
60. A peptide of claim 58 which is conjugated to a carrier protein or a carrier peptide.
61. A composition comprising a peptide of claim 58 together with a pharmaceutically or diagnostically acceptable carrier.
62. A vaccine composition comprising a peptide of claim 58 together with a physiologically acceptable carrier.
63. A method for detecting antibodies to HTLV-III, HIV or AIDS virus in a physiological sample which comprises the steps of:
(a) providing at least one peptide of daim 58, (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide-antibody complex is formed, (c) detecting the presence of said peptide-antibody complex.
(a) providing at least one peptide of daim 58, (b) contacting said peptide with said sample for sufficient time and under suitable conditions to allow an immunological reaction to occur between said peptide and said antibodies whereby a peptide-antibody complex is formed, (c) detecting the presence of said peptide-antibody complex.
64.
A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 58 which is bonded to the solid support.
A test kit for detecting antibodies to HTLV-III, HIV or AIDS virus comprising:
(a) a container (b) a solid support (c) a peptide of claim 58 which is bonded to the solid support.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72805285A | 1985-04-29 | 1985-04-29 | |
US728,052 | 1985-04-29 | ||
US06/767,303 US4629783A (en) | 1985-04-29 | 1985-08-19 | Synthetic antigen for the detection of AIDS-related disease |
US767,303 | 1985-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1341605C true CA1341605C (en) | 2010-05-18 |
Family
ID=27111625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA507755A Active CA1341605C (en) | 1985-04-29 | 1986-04-28 | Synthetic antigen for the detection of aids-related disease |
Country Status (5)
Country | Link |
---|---|
US (2) | US4629783A (en) |
CA (1) | CA1341605C (en) |
ES (1) | ES8708058A1 (en) |
GR (1) | GR861099B (en) |
IE (1) | IE66921B1 (en) |
Families Citing this family (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525300A (en) * | 1983-01-07 | 1985-06-25 | Japanese Foundation For Cancer Research | Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies |
US7205102B1 (en) | 1983-09-15 | 2007-04-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA |
US5217861A (en) * | 1983-09-15 | 1993-06-08 | Institut Pasteur | Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor |
US7232654B1 (en) | 1983-09-15 | 2007-06-19 | Institut Pasteur | DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) |
US5173400A (en) * | 1983-09-15 | 1992-12-22 | Institut Pasteur | Antibody detection of antibodies to viral proteins in serum |
GB8429099D0 (en) | 1984-11-16 | 1984-12-27 | Pasteur Institut | Closed dna sequences |
GB8423659D0 (en) | 1984-09-19 | 1984-10-24 | Pasteur Institut | Cloned dna sequences |
US5374519A (en) * | 1983-12-05 | 1994-12-20 | Institut Pasteur | Oligopeptides comprising p18 protein of human immunodeficiency virus (HIV), compositions comprising peptides of p18 protein of HIV, and diagnostic kits and methods for detecting acquired immune deficiency syndrome (AIDS) |
US5610035A (en) * | 1983-12-05 | 1997-03-11 | Institut Pasteur Centre National De La Recherche Scientific | Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies |
US7351412B1 (en) | 1983-12-05 | 2008-04-01 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
US7045130B1 (en) | 1984-10-18 | 2006-05-16 | Institut Pasteur | Antibodies against antigens of human immunodeficiency virus (HIV-1) |
US5705612A (en) | 1984-10-18 | 1998-01-06 | Institut Pasteur And Centre National De La Recherche Scientifique | NEF peptide encoded by human immunodefiency virus type 1 (HIV-1) |
US7273695B1 (en) * | 1984-10-31 | 2007-09-25 | Novartis Vaccines And Diagnostics, Inc. | HIV immunoassays using synthetic envelope polypeptides |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
US7285271B1 (en) * | 1984-10-31 | 2007-10-23 | Novartis Vaccines And Diagnostics, Inc. | Antigenic composition comprising an HIV gag or env polypeptide |
US6894152B1 (en) | 1984-11-16 | 2005-05-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
US4784941A (en) * | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
FR2580177B2 (en) * | 1985-04-15 | 1989-06-02 | Pasteur Institut | AIDS VIRUS ENVELOPE GLYCOPROTEIN-RELATED ANTIGENS, IN PARTICULAR PRECURSORS OF SUCH GLYCOPROTEIN, PROCESSES FOR OBTAINING SUCH ANTIGENS, AND MEANS USED IN SUCH PROCESSES, APPLICATIONS OF SUCH ANTIGENS TO THE PREPARATION OF IMMUNOGEN COMPOSITIONS AIDS OR RELATED CONDITIONS |
US5773210A (en) * | 1985-04-19 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS |
NZ215867A (en) * | 1985-04-19 | 1989-10-27 | Hoffmann La Roche | Aids envelope protein, dna vectors and method of production |
EP0220273B2 (en) * | 1985-04-29 | 2007-01-17 | Bio-Rad Laboratories, Inc. | Synthetic antigens for the detection of aids-related disease |
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
JP2564268B2 (en) * | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | Fusion antigen polypeptide |
US4777127A (en) * | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4956273A (en) * | 1985-10-24 | 1990-09-11 | Southwest Foundation For Biomedical Research | Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC |
CS256960B1 (en) * | 1985-11-16 | 1988-04-15 | Viktor Krchnak | Peptides with properties of antigenic determinants and method of their production |
US6086880A (en) * | 1985-12-26 | 2000-07-11 | The University Of Saskatchewan | Rotavirus peptide compositions and methods of use |
US6514691B1 (en) | 1986-01-22 | 2003-02-04 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2 |
US6544728B1 (en) * | 1986-01-22 | 2003-04-08 | Institut Pasteur | Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2 |
US5310651A (en) * | 1986-01-22 | 1994-05-10 | Institut Pasteur | DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2 |
ES2013295B3 (en) | 1986-01-22 | 1990-05-01 | Pasteur Institut | RETROVIRUSES OF THE HIV-2 TYPE SUSCEPTIBLE TO CAUSE AIDS, ITS ANTIGENIC AND NUCLEIC CONSTITUENTS. |
US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
US5306614A (en) * | 1986-01-22 | 1994-04-26 | Institut Pasteur | Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2) |
US5830641A (en) * | 1986-01-22 | 1998-11-03 | Institut Pasteur | In vitro diagnostic assays for the detection of HIV-1 or HIV-2 employing viral-specific antigens and antibodies |
US5580739A (en) * | 1986-01-22 | 1996-12-03 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2 |
US6265149B1 (en) | 1986-01-22 | 2001-07-24 | Institut Pasteur | In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies |
US5079342A (en) * | 1986-01-22 | 1992-01-07 | Institut Pasteur | Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits |
US5364933A (en) | 1986-03-03 | 1994-11-15 | Institut Pasteur | Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2) |
US5066782A (en) * | 1986-01-22 | 1991-11-19 | Institut Pasteur | Retrovirus capable of causing AIDS, means and method for detecting it in vitro |
IT1204775B (en) * | 1986-01-31 | 1989-03-10 | Rosella Silvestrini | KIT FOR THE DETERMINATION OF THE PROLIFERATIVE ACTIVITY IN HUMAN TUMORS |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
US4753873A (en) * | 1986-02-03 | 1988-06-28 | Cambridge Bioscience Corporation | Peptides for the diagnosis of HTLV-III antibodies, their preparation and use |
US4808536A (en) * | 1986-02-27 | 1989-02-28 | Centocor, Inc. | Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein |
US6054565A (en) | 1986-03-03 | 2000-04-25 | Institut Pasteur | Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2 |
DE3788397T3 (en) * | 1986-03-24 | 2003-11-27 | Ortho Pharma Corp | SYNTHETIC HTLV III PEPTIDE COMPOSITIONS AND THEIR USE. |
US5075211A (en) * | 1986-03-26 | 1991-12-24 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US6130314A (en) * | 1986-03-26 | 2000-10-10 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4879212A (en) * | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
US4904581A (en) * | 1986-05-06 | 1990-02-27 | Epitope, Inc. | Method of detecting AIDS virus infection |
US4917998A (en) * | 1986-05-06 | 1990-04-17 | Epitope, Inc. | Method of detecting AIDS virus infection |
DE3789633T2 (en) * | 1986-05-27 | 1994-08-04 | Hoffmann La Roche | HTLV-III (LAV) blanket peptides. |
US4957737A (en) * | 1986-05-27 | 1990-09-18 | Hoffmann-La Roche Inc. | HTLV-III (LAV) envelope peptides |
US5276016A (en) * | 1986-06-03 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Small peptides which inhibit binding to T-4 receptors and act as immunogens |
US5529983A (en) * | 1986-06-03 | 1996-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Use of small peptides in the treatment of psoriasis |
US4816387A (en) * | 1986-06-06 | 1989-03-28 | Bio-Research Laboratories, Inc. | Method for detection of antibodies to HTLV-III and diagnostic test kit useful therewith |
US4943627A (en) * | 1986-06-12 | 1990-07-24 | Biogen, Inc. | Peptides involved in the pathogenesis of HIV infection |
JPH01501547A (en) * | 1986-06-12 | 1989-06-01 | バイオジェン ナームローズ ベンノットシャップ | Peptides related to the pathogenesis of HIV infection |
US5017688A (en) * | 1986-06-12 | 1991-05-21 | Biogen, Inc. | Peptides involved in the pathogenesis of HIV infection |
WO1987007957A1 (en) * | 1986-06-20 | 1987-12-30 | The Regents Of The University Of California | Low-level detection of human immunodeficiency virus |
US5087557A (en) * | 1986-06-23 | 1992-02-11 | Genetic Systems Corporation | Human monoclonal antibody to lymphadenopathy-associated virus |
US5824482A (en) * | 1986-06-23 | 1998-10-20 | Institut Pasteur | Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL |
US5030714A (en) | 1986-06-23 | 1991-07-09 | Institut Pasteur | Variant of LAV viruses |
JPH01500432A (en) * | 1986-07-21 | 1989-02-16 | サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ | Compositions and methods for immunizing against viral agents of AIDS and ARC |
US5142025A (en) * | 1986-08-01 | 1992-08-25 | Repligen Corporation | Recombinant HTLV-III proteins and uses thereof |
US5110906A (en) * | 1986-08-21 | 1992-05-05 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
US5126433A (en) * | 1986-08-21 | 1992-06-30 | The Trustees Of Columbia University In The City Of New York | Soluble forms of the t cell surface protein cd4 |
US6673896B1 (en) | 1986-08-21 | 2004-01-06 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
DE3751751T2 (en) | 1986-08-21 | 1996-10-17 | Univ Columbia | DNA ENCODING THE T CELL SURFACE PROTEIN T4 AND USE OF T4 FRAGMENTS IN THE TREATMENT OF AIDS |
US5958678A (en) * | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
DE3638767A1 (en) * | 1986-11-13 | 1988-05-26 | Behringwerke Ag | INCUBATION MEDIUM CONTAINING LACTOTRINE FOR SOLID-PHASE IMMUNOMETRIC METHOD AND ITS USE |
US5081226A (en) * | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
AU592258B2 (en) * | 1986-12-30 | 1990-01-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins |
ATE154808T1 (en) * | 1987-01-16 | 1997-07-15 | Pasteur Institut | PEPTIDES WITH THE IMMUNOLOGICAL PROPERTIES OF HIV-2 |
US6322964B1 (en) * | 1987-01-16 | 2001-11-27 | Genetic Systems Corporation | Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies |
FR2610632B1 (en) * | 1987-02-11 | 1990-12-21 | Pasteur Institut | CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS |
AU1366088A (en) * | 1987-01-28 | 1988-08-24 | Ortho Pharmaceutical Corporation | Immunosuppressive peptides and methods of use |
US4861707A (en) * | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
US5141867A (en) * | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
ATE108457T1 (en) * | 1987-03-25 | 1994-07-15 | Genetic Systems Corp | SYNTHETIC ANTIGENS FOR DETERMINING AIDS-RELATED DISEASES CAUSED BY LAV-2. |
NO881151L (en) * | 1987-03-27 | 1988-09-28 | Syntello Ab | SYNTHETIC HIV-1 ANTIGEN. |
AU614521B2 (en) * | 1987-04-16 | 1991-09-05 | Johnson & Johnson | Stlv-iii-related polypeptides, diagnostic systems and assay methods |
SE8701628D0 (en) * | 1987-04-16 | 1987-04-16 | Erling Norrby | MEANS OF ANALYSIS MM |
AU1711888A (en) * | 1987-04-24 | 1988-12-02 | Biogen, Inc. | Immunotherapeutic methods and compositions |
US4921787A (en) * | 1987-05-01 | 1990-05-01 | Cambridge Bioscience Corporation | Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex |
US5104790A (en) * | 1987-06-29 | 1992-04-14 | Genetic Systems Corporation | Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use |
DK362287D0 (en) * | 1987-07-13 | 1987-07-13 | Kurt Baekgaard Osther | METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-1 ANTIBODIES |
ATE128738T1 (en) * | 1987-07-13 | 1995-10-15 | Verigen Inc | METHOD FOR THE RAPID AND SENSITIVE DETECTION OF IGM ANTIBODIES AGAINST RETROVIRAL ANTIGENS. |
EP0324834B1 (en) * | 1987-07-13 | 1995-11-08 | Verigen, Inc. | Method for rapid and sensitive detection of hiv-i antibodies |
US5447837A (en) * | 1987-08-05 | 1995-09-05 | Calypte, Inc. | Multi-immunoassay diagnostic system for antigens or antibodies or both |
EP0329761B1 (en) * | 1987-08-21 | 1993-12-01 | Scripps Clinic And Research Foundation | Hiv-1-related polypeptides, diagnostic systems and assay methods |
US5086002A (en) * | 1987-09-07 | 1992-02-04 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
SE8704185L (en) * | 1987-10-28 | 1989-04-29 | Ferring Ab | NEW PEPTIDES, ARTIFICIAL ANTIGENS AND IMMUNO ANALYSIS TEST RATES |
EP0316495A1 (en) * | 1987-11-19 | 1989-05-24 | Iaf Biochem International Inc. | Synthetic peptides useful for the detection of aids-related antibodies in human sera |
WO1989005821A1 (en) * | 1987-12-21 | 1989-06-29 | Arch Development Corporation | Hiv-related antigens and antibodies |
US6210874B1 (en) | 1988-01-27 | 2001-04-03 | Biochem Immunosystems, Inc. | Synthetic peptides and mixtures thereof for detecting HIV antibodies |
US5241047A (en) * | 1988-12-08 | 1993-08-31 | Biochem Pharma Inc. | Synthetic peptides and mixtures thereof for detecting HIV antibodies |
US6218102B1 (en) * | 1988-01-27 | 2001-04-17 | Biochem Immunosystems, Inc. | Synthetic peptides and mixtures thereof for detecting HIV antibodies |
US6214537B1 (en) * | 1988-01-27 | 2001-04-10 | Biochem Immunosystems, Inc. | Synthetic peptides and mixtures thereof for detecting HIV antibodies |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
EP0330359A3 (en) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
US5562905A (en) * | 1988-04-26 | 1996-10-08 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
ATE134195T1 (en) * | 1988-06-10 | 1996-02-15 | United Biomedical Inc | PEPTIDE FRAGMENTS OF HIV |
HUT58764A (en) * | 1988-07-08 | 1992-03-30 | Smithkline Beckman Corp | Process for producing peptides, pharmaceutical compositions containing them and amino-acid intermediates |
US5354846A (en) * | 1988-11-18 | 1994-10-11 | Michael Kehoe | Streptolysin O antigen derivatives, its production and uses |
GB8828097D0 (en) * | 1988-12-01 | 1989-01-05 | Wellcome Found | Peptides |
JP2994031B2 (en) * | 1988-12-20 | 1999-12-27 | クラリティ テクノロジーズ インコーポレイテッド | Method for determining the presence or amount of HIV-1 or HIV-2 antibody, immunospecific reagent, synthetic peptide, diagnostic kit, method for preparing HIV-1 or HIV-2 antibody, immunogen and antibody |
US5196510A (en) * | 1988-12-29 | 1993-03-23 | Cytogen Corporation | Molecular recognition units |
US5439792A (en) * | 1989-06-02 | 1995-08-08 | Genetic Systems Corporation | Cysteine thiol-protected peptides for use in immunoassays |
US6083504A (en) * | 1989-08-24 | 2000-07-04 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) |
JP2807287B2 (en) * | 1989-10-13 | 1998-10-08 | 株式会社医学生物学研究所 | Peptides and their uses |
US5480967A (en) * | 1990-01-05 | 1996-01-02 | United Biomedical, Inc. | HIV-1 core protein fragments |
DE69129207T2 (en) * | 1990-01-16 | 1998-10-08 | Orgenics Ltd | Peptides derived from virus-HIV-envelope glycoproteins, their use for the detection of infection of these viruses and for the vaccination against AIDS |
EP0511216A4 (en) * | 1990-01-16 | 1993-05-05 | Prutech Res Dev Partnership Ii | Combination assay for antibody or antigen |
US5639594A (en) * | 1990-02-16 | 1997-06-17 | United Biomedical, Inc. | Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis |
FR2663034B1 (en) * | 1990-06-06 | 1995-04-21 | Neosystem Sa | PEPTIDES OF THE SM-D ANTIGEN AND THEIR USE IN PARTICULAR FOR THE DIAGNOSIS OF DISSEMINED LUPUS ERYTHEMATOUS. |
US5359029A (en) * | 1990-07-18 | 1994-10-25 | Biochem Immunosystems Inc. | Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-I and HTLV-II viruses |
ATE172542T1 (en) * | 1990-08-16 | 1998-11-15 | Diagnostic Biotech Inc | ENLARGED WESTERN BLOT FORMAT AND AN IMMUNO TEST METHOD FOR THE DETERMINATION OF VIRAL ANTIBODIES |
DE4039925A1 (en) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | SELECTED PEPTIDES OF THE GROUP-SPECIFIC ANTIGEN (GAG) OF HUMANEM IMMUNE DEFICIENCY VIRUS (HIV), THEIR PRODUCTION AND USE |
US5753488A (en) * | 1991-05-23 | 1998-05-19 | Martin; William John | Isolated stealth viruses and related vaccines |
US6685939B2 (en) | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US5994514A (en) * | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
AU665409B2 (en) * | 1992-02-10 | 1996-01-04 | Baxter International Inc. | Method for testing blood units for viral contamination |
US7326535B2 (en) | 1993-09-15 | 2008-02-05 | Ortho Diagnostic Systems Inc. | Immunoreactive peptides from Epstein-Barr virus |
US7060283B1 (en) | 1992-09-15 | 2006-06-13 | Ortho Diagnostic Systems, Inc. | Immunoreactive peptides from Epstein-Barr virus |
ES2126620T5 (en) * | 1992-10-06 | 2010-05-21 | Siemens Healthcare Diagnostics Products Gmbh | RETROVIRUS OF THE HIV GROUP AND ITS USE. |
EP0697888B1 (en) | 1993-05-12 | 2003-09-17 | Chiron Corporation | Conserved motif of hepatitis c virus e2/ns1 region |
US6103237A (en) * | 1993-07-22 | 2000-08-15 | Hybritech Incorporated | Stable variant hK2 polypeptide |
US20040259113A1 (en) * | 1993-07-22 | 2004-12-23 | Mayo Foundation For Medical Education And Research, Hybritech Incorporated | Method for detection of metastatic prostate cancer |
US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
DE4405810A1 (en) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Peptides derived from a retrovirus from the HIV group and their use |
EP0804593A1 (en) * | 1994-05-10 | 1997-11-05 | Mayo Foundation For Medical Education And Research | Recombinant hk2 polypeptide |
US6506553B1 (en) | 1995-03-30 | 2003-01-14 | Ortho Diagnostics Systems, Inc. | Method for diagnosis of Epstein-Barr virus associated disease |
US20030036106A1 (en) * | 1996-10-28 | 2003-02-20 | Burke Thomas J. | Kinase and phosphatase activity measurement using fluorescence polarization |
US6479263B1 (en) | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) * | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US20030118985A1 (en) * | 1997-05-14 | 2003-06-26 | Hunt Jeffrey C. | Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein |
AU8259798A (en) | 1997-06-20 | 1999-01-04 | George G Klee | Method for detection of breast cancer |
JP4166940B2 (en) * | 1997-08-01 | 2008-10-15 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | Synthetic antigens for detection of antibodies immunoreactive with HIV virus |
EP0957365B1 (en) * | 1997-09-05 | 2006-02-01 | Matsushita Electric Industrial Co., Ltd. | Fluorescence polarization method |
US6749856B1 (en) * | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
SE9703531D0 (en) * | 1997-09-30 | 1997-09-30 | Rudolf Valenta | Non-anaphlactic forms of allergens and their use |
CN1213068C (en) * | 1999-12-23 | 2005-08-03 | 医疗研究局 | Improvments in or relating to immune responses to HIV |
KR100768174B1 (en) * | 2000-12-06 | 2007-10-17 | 삼성에스디아이 주식회사 | Electron gun for cathode ray tube |
DE60336978D1 (en) | 2003-04-11 | 2011-06-16 | Pasteur Institut | Synthetic peptide HIV vaccine: the CBD epitope as an efficient immunogen for the induction of HIV-neutralizing antibodies |
US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
AU2005267607B8 (en) * | 2003-09-11 | 2009-07-16 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
EP1673633B9 (en) * | 2003-09-11 | 2011-03-02 | Idexx Laboratories, Inc. | Method for detecting feline immunodeficiency virus |
AU2004304348B2 (en) * | 2003-12-18 | 2009-02-26 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
CN1901931A (en) * | 2004-01-07 | 2007-01-24 | 特里梅里斯公司 | HIV gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus |
DE602005027326D1 (en) * | 2004-02-19 | 2011-05-19 | Idexx Lab Inc | METHOD AND DEVICE FOR DETECTING CAT IMMUNE WEAK VIRUS |
EP1761564A1 (en) * | 2004-06-30 | 2007-03-14 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
JP4866848B2 (en) * | 2004-06-30 | 2012-02-01 | アイデックス ラボラトリーズ インコーポレイテッド | Methods and apparatus for detecting FIV comprising the use of peptides derived from the V3 region of the ENV protein of feline immunodeficiency virus (FIV) |
EP1781822B1 (en) * | 2004-08-20 | 2014-11-12 | Siemens Healthcare Diagnostics Inc. | Methods and materials for detecting mutations in quasispecies having length polymorphism |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2007097903A2 (en) * | 2006-02-02 | 2007-08-30 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
WO2008124013A1 (en) * | 2007-04-03 | 2008-10-16 | Trimeris, Inc. | Novel formulations for delivery of antiviral peptide therapeutics |
EP2173902A4 (en) * | 2007-07-03 | 2013-01-09 | Mt Sinai Hospital | Therapeutics and diagnostics for group a streptococci |
MX2010003179A (en) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Methods of synthesis for therapeuthic anti-hiv peptides. |
EP2553452B1 (en) | 2010-04-02 | 2015-03-04 | IDEXX Laboratories, Inc. | Detection of feline immunodeficiency virus |
CN115216451A (en) | 2021-04-16 | 2022-10-21 | 硕腾服务有限责任公司 | Pseudorabies virus vaccine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US475896A (en) * | 1892-05-31 | Cable-grip | ||
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
US4520113A (en) * | 1984-04-23 | 1985-05-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
US4784941A (en) * | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
EP0220273B2 (en) * | 1985-04-29 | 2007-01-17 | Bio-Rad Laboratories, Inc. | Synthetic antigens for the detection of aids-related disease |
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
US4803156A (en) * | 1985-09-11 | 1989-02-07 | New York Blood Center | Peptide-beta-lactamase conjugates for enzyme-linked immunoassays |
US4956273A (en) * | 1985-10-24 | 1990-09-11 | Southwest Foundation For Biomedical Research | Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC |
US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
US4753873A (en) * | 1986-02-03 | 1988-06-28 | Cambridge Bioscience Corporation | Peptides for the diagnosis of HTLV-III antibodies, their preparation and use |
US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
US4808536A (en) * | 1986-02-27 | 1989-02-28 | Centocor, Inc. | Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein |
US4879212A (en) * | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
US5017688A (en) * | 1986-06-12 | 1991-05-21 | Biogen, Inc. | Peptides involved in the pathogenesis of HIV infection |
US5034511A (en) * | 1987-04-13 | 1991-07-23 | Institut Pasteur | Variant of LAV viruses |
US4861707A (en) * | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
US4943628A (en) * | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
-
1985
- 1985-08-19 US US06/767,303 patent/US4629783A/en not_active Expired - Lifetime
-
1986
- 1986-04-25 GR GR861099A patent/GR861099B/en unknown
- 1986-04-28 IE IE112186A patent/IE66921B1/en not_active IP Right Cessation
- 1986-04-28 ES ES554453A patent/ES8708058A1/en not_active Expired
- 1986-04-28 CA CA507755A patent/CA1341605C/en active Active
-
2002
- 2002-11-26 US US10/305,271 patent/US20030211117A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES554453A0 (en) | 1987-09-01 |
IE66921B1 (en) | 1996-02-07 |
GR861099B (en) | 1986-09-25 |
US4629783A (en) | 1986-12-16 |
ES8708058A1 (en) | 1987-09-01 |
US20030211117A1 (en) | 2003-11-13 |
IE861121L (en) | 1986-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1341605C (en) | Synthetic antigen for the detection of aids-related disease | |
US6485900B1 (en) | Synthetic antigen for the detection of AIDS-related disease | |
US5075211A (en) | Synthetic antigen for the detection of AIDS-related disease | |
US5439792A (en) | Cysteine thiol-protected peptides for use in immunoassays | |
EP0247557A2 (en) | HTLV-III(LAV) Envelope peptides | |
US6322964B1 (en) | Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies | |
EP0284383B1 (en) | Synthetic antigens for the detection of aids-related disease caused by LAV-2 | |
US7144697B1 (en) | Synthetic antigen for the detection of antibodies immunoreactive with HIV virus | |
AU652919B2 (en) | Cysteine thiol-protected peptides for use in immunoassays | |
US6130314A (en) | Synthetic antigen for the detection of AIDS-related disease | |
AU597884C (en) | Synthetic antigens for the detection of AIDS-related disease | |
AU623949B2 (en) | Synthetic peptide derivatives of gp41 glycoprotein of HIV | |
JP2705791B2 (en) | Synthetic antigens for detection of AIDS-related diseases | |
Cogniaux et al. | Characterization of monoclonal antibodies against the p17 core protein of the human immunodeficiency virus 1 | |
NO173034B (en) | PROCEDURES AND PEPTIDES FOR DETECTION OF AIDS-RELATED DISEASE |